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Abstract
Numerous common and severe human muscle disorders could benefit from stem 
cell therapy that would allow replacement o f degenerating muscle. A recent upsurge of 
reports, claiming that readily accessible haematopoietic stem cells (HSCs) participate in 
muscle regeneration, raises hopes for their clinical application. However, the biology of 
this process and the proof o f the ability of HSCs to be reprogrammed remain elusive. 
Using murine bone marrow (BM) cells, carrying different reporter cassettes controlled 
by elements of the muscle-specific Myf5, MLC3F and MCK  promoters, we 
demonstrated that haematopoietic cells in co-culture with myoblasts express muscle- 
specific genes. In spite of this, these cells show limited regeneration o f muscle in PaxTf~ 
mice and never give rise to myoblast clones. Correspondingly, the gene expression 
profiling of haematopoietic CD45+/Scal+ cells revealed partial but extended myogenic 
reprogramming, despite the absence of key myogenic transcription factors such as Pax7 
and MyoD. Indeed, BM transplantation and co-culture experiments, using BM cells 
from PaxTA or MyoD'A mice, suggested that neither Pax7 nor MyoD are essential for 
the participation of haematopoietic cells in muscle regeneration, indicating that the Pax7 
pathway is not active in these cells. In-vitro experiments with muscle cells from PaxTA 
/Myf5nlacZ/+ and Pax7'/7MLC3F-nlacZ-E mice confirmed the tight association o f Pax7 
with the muscle-stem-cell characteristics. Additionally, the Pc^7 ectopic expression in 
BM cells infused to them the ability to generate myogenic clones "and increased their in- 
vivo myogenic potential. Overall, our results demonstrate that BM-derived 
CD45+/Scal+ cells, while undergoing myogenic specification and differentiation, cannot 
be considered muscle stem cells, and this latter distinction from the satellite cells is 
most probably due to the inactivity of the Pax7 pathway.
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1 Introduction
1.1 Stem cell biology: a brief overview.
The multicellular organisms are formed by the long-lasting cell division of one 
single cell, the zygote. In addition, the cells o f most tissues can be damaged or die and 
therefore must be replaced. This need for continuous cell divisions and cell replacement 
during development and adult life, respectively, is met by a category of "reserve" cells 
called stem cells. These cells can self-renew (i.e. generate daughter cells identical to 
themselves) for long periods and extensively contribute to organ formation and tissue 
maintenance and regeneration. This unique tissue generation capacity is due to their in- 
vivo ability to proliferate and differentiate in several cell types, in large numbers. They 
have been isolated both from the embryo and the adult organism, and according to their 
ability to give one or more differentiated cell types they are categorised in totipotent, 
pluripotent, multipotent or unipotent (Table 1).
In mammals, the zygote and the early blastomeres, until the eight-cell stage, are 
totipotent and remain plastic 1. They undergo cleavage divisions and lack the capacity to 
self-renew. After the formation of the blastocyst, the embryonic stem (ES) cells appear. 
These cells had been initially isolated in the early 1980s from the inner cell mass (ICM) 
of mouse blastocyct2,3 and later by the human one 4. ES cells can propagate indefinitely 
and differentiate inot wide variety o f cell types in vitro. The injection of both mouse and 
human ES cells in adult mice results in the formation of teratocarcinomas that contain 
derivatives of all three primary germ layers (endoderm, mesoderm and ectoderm) 2’4. In 
addition, the insertion of mouse ES cells into mouse blastocysts leads to the creation of  
chimaeric mice that contain donor-derived cells in all the adult tissues. These above- 
mentioned qualities demonstrate that ES cells can give rise to all cell types and
therefore their pluripotency (Figure 1). Furthermore, they can also generate early 
haematopoietic precursor cells 5, cardiomyocytes 6 and other adult cell types (Figure 2). 
Although, this latter characteristic makes them excellent candidates for regenerative 
medicine, the formation of teratomas after their in-vivo transplantation and the ethical 
issues, concerning their derivation from early human embryos, currently forbid their 
clinical use.
More recently, adult stem cells have also been identified and represent an 
alternative source for cell transplantation. Nowadays, we know that they exist in most if  
not all tissues, including bone marrow (BM), intestine, epidermis, bone and muscle, and 
as mentioned before they are responsible for the replacement of the terminally 
differentiated cells. In contrast to ES cells, these cells are already determined and 
therefore they are generally more restricted to their differentiation potential 7. Their 
characteristics differ according to the tissue in which contribute and its renewal needs, 
but they all act through the creation of an intermediate population of amplifying cells 
prior to their terminal differentiation (Figure 3).
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Cell category Cell example Characteristics
Totipotent Zygote and very early Construct the whole organism
blastomeres by itself.
Pluripotent Embryonic stem cells (ES) Give rise to all cell types and
contribute to all the tissues of
the organism.
Multipotent Haematopoietic stem cells Give rise to multiple cell types.
(HSC)
Unipotent Muscle stem cells Differentiate only in one
specific cell type.
Table 1. Stem cell classification.
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Totipotency Pluripotency
Zygote Blastocyst  ES cells
K
oc
Materna factors Embryonic expression
Cleavage division Cell division
No self-renewal Self renewal possible
Intrinsic regulation Responsive to exterra  signals
X inactivation X reactivation
Figure 1. The Transition from Totipotency to Pluripotency1.
In mammals, the zygote and the first eight cells formed, which are identical to each 
other, are the only cells that have the potential to create the whole organism (totipotent). 
This property is lost after the eight-cell stage, however the cells isolated from the inner 
mass of the blastocyst, called embryonic stem cells, retain their ability to give rise to all 
three germ layers and therefore to all the tissues of the adult organism (pluripotent).
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Figure 2. Differentiation Potential of Embryonic Stem (ES) Cells7.
The pluripotency of the embryonic stem cells isolated from the inner cell mass of the 
blastocyst is not restricted to their potential to contribute to the formation of all tissues 
during development. Under the correct culture conditions, these cells can also 
differentiate in several cell types of the adult mouse, such as haematopoietic and neural 
cells.
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Stem cell Transit Differentiated
amplifying cell
cell
Figure 3. Mechanism of Action Adult Stem Cells7.
The adult stem cells are found on the top of the lineage hierarchy and are committed to 
a specific cell lineage. Once they are activated, self-renew and/or proliferate to produce 
large numbers of transit amplifying cells. Finally, the propagation capacity of these cells 
is exhausted and they terminally differentiate to the desired cell type.
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1.1.1 Haematopoietic Stem Cells.
The most studied adult stem cells are the haematopoietic stem cells (HSC). These 
cells were initially thought to remain quiescent until their activation and differentiation, 
but it is now known that they are slow-cycling cells. BrdU incorporation and cell cycle 
analysis experiments showed that 8% of them enter the cell cycle per day and 99% 
divide every 1-2 months (these frequencies are increased in older mice 8). This 
continuous cell division necessitates the existence of a self-renewal mechanism for the 
maintenance of HSCs during lifetime 9. The size of this reserved cell pool is also 
regulated by apoptosis, since the over-expression of the anti-apoptotic Bel-2 in HSCs 
conferred protection against irradiation-induced cell death 10 and a repopulation 
advantage in comparison to wild type HSCs, as revealed by competitive transplantation 
experiments 11. Notably, parabiosis experiments (during which the circulation of two
mice is surgically joined) demonstrated that HSCs periodically leave their BM niche,
1 0travel in the circulation and return to the BM, in which they re-engraft . This 
physiological migration is regulated by chemokine receptors (e.g. CXCR4) and 
adhesion molecules 13, like P- and E-selectin 14 and VCAM-1 (vascular cell adhesion 
molecule-1) 15.
HSCs are adult multipotent stem cells and give rise both to the red and all the 
white blood cells 16. Remarkably, the transplantation o f a single HSC into a mouse, 
whose own haematopoietic cells have been previously depleted by whole-body gamma 
irradiation, rescues the animal from anaemia-caused death. This is accomplished thanks 
to the ability of this single HSC to repopulate completely the haematopoietic system 17. 
A similar practice is followed for the treatment of human patients affected by 
leukaemia. In this case, irradiation or cytotoxic drugs are administered to kill the tumour 
blood cells, which are subsequently replaced by the healthy donor cells 18.
The separation of several BM-derived subpopulations, using specific cell-surface 
proteins as markers and flow cytometry sorting, has allowed the fine characterization 
and distinction o f the haematopoietic stem/progenitor cells according to their diverse in- 
vivo repopulating capacity and in-vitro differentiation properties. Today, we can 
recognize two populations that can be considered HSCs, the long-term (LT-HSC: Thy- 
l lowLin'Scal+Mac-rCD4'c-kit+) and the short-term (ST-HSC: Thy-llowLin'Scal+Mac- 
l lowCD4'c-kit+) ones. They differ from each other in the length o f the time period for 
which they can reconstitute the haematopoietic system of a mouse following irradiation 
and transplantation, reflecting their diverse self-renewal capacity. The LT-HSCs can 
provide the necessary haematopoietic cells and identical daughter LT-HSCs for the 
whole life of the mouse. On the contrary, the ST-HSCs are able to produce 
haematopoietic cells only for a limited period of time, and cannot generate any LT- 
HSCs but only daughter ST-HSCs and multipotent progenitors (MPP: Thy-l'Lin' 
Scal+Mac-l'CD4lowc-kit+), which do not bear self-renewal ability at all 19. Similar 
transplantation experiments allowed the identification o f a common lymphoid 
progenitor (CLP, Lin' IL-7R+Thy-rSca-llowc-KitIow cells) and a common myeloid 
progenitor (CMP, Lin' IL-7R'Thy-rSca-l'c-Kit+ cells) that display lymphoid-restricted 
(T, B, and NK cells) 20 and myeloid/erythroid-restricted (megakaryocyte/erythrocyte or 
granulocyte/macrophage progenitors) 21 reconstitution and differentiation capacity, 
respectively (Figure 4).
The developmental origin of HSCs remains controversial. In mice, the first 
haematopoietic cells are detected in the yolk sac (YS) at embryonic day 7 (E7), as 
shown by the in-vitro detection of both erythroid and macrophage progenitors 22. These 
cells are multipotent progenitors, since in-vitro cultures of clones derived from YS 
between E8.5 and E9.5 can give rise both to pre-B-cell and myeloid clones 23. However, 
they cannot reconstitute in vivo the haematopoietic system of lethally irradiated adult
mice and therefore are not considered ancestors of HSCs. Between E7.5 and E10, 
another haematopoietic site exists in the paraaortic splanchnopleura/aorta-gonad- 
mesonephros region (PAS/AGM). AGM keeps its haematopoietic capacity for a few 
days and its relationship with YS is uncertain. In-vitro culture o f cells isolated from 
PAS (E7.5-E9) resulted in the formation of B and T cell clones 24. In addition, the 
transfer of AGM-derived cells (E10) into adult irradiated recipient mice accomplished 
the complete repopulation of the mice, demonstrating that this region contains cells with 
HSC activity 25. Indeed, it is hypothesised that these cells initially colonise the liver (the 
most potent embryonic haematopoietic tissue) and finally the spleen and the BM (the 
definitive haematopoietic organ) after El 5. Although, these findings suggest that the 
definitive HSCs appear already at E10 in AGM, it is still in doubt whether the adult 
BM-derived HSCs originate from these primitive cells with HSC characteristics or
appear only later in development. This latter idea is supported by the distinct gene
26expression profile between the embryonic and adult haematopoietic cell populations .
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Figure 4. Model of HSC Differentiation 21.
The LT-HSCs can self-renew and/or generate ST-HSCs for the organism's lifetime. The 
ST-HSCs are also able to self-renew and produce multipotent, non-self-renewal 
progenitors (MPP), but for a limited time period. MPPs are the last type of cells in the 
hierarchy that can give rise both to the myeloid and the lymphoid lineage, and operate 
through intermediate progenitors called common myeloid progenitors (CMP) and 
common lymphoid progenitors (CLP), respectively. This cascade continues with the 
generation of more progenitors that progressively become more committed, e.g. 
myelomonocytic progenitors (GMP) and megakaryotic/erythroid progenitors (MEP) are 
the progeny of the CMPs, and finally ends with the differentiation of unipotent 
precursors into the desired cell types, e.g. B cells from the B progenitors (pro-B).
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1.1.2 Muscle-resident myogenic stem/progenitor cells.
1.1.2.1 Satellite Cells.
At variance with HSCs, other adult stem cells are not so well studied. More 
recently, though, a great effort has been made to identify more adult stem cells and to 
investigate their mechanisms of action. The potential clinical applications o f the muscle 
stem cells in diseases, like muscular dystrophy, has promoted the stem-cell research in 
muscle biology in the last decades. Remarkably, the skeletal muscle stem cells, also 
termed satellite cells, have been discovered since the 1960s. They are defined as the 
mononuclear cells located between the basal lamina and the plasma membrane o f the 
adult-mouse myoflber and their role is the postnatal growth and the muscle repair 
(Figure 5) . These cells have very high nucleus/cytoplasm and
heterochromatin/euchromatin ratios and they contain a reduced number o f organelles 
qualitatively and quantitatively, suggesting an inactive state 29. Their distinct in-vitro 
differentiation characteristics 30 and gene expression patterns 31, compared with the 
embryonic and the foetal myoblasts ones, strongly suggest that they are indeed a 
separate cell population restricted to the late embryo and the adult mouse.
Unfortunately, the above spatiotemporal definition is not accurate enough and 
consequently satellite cells are not identical to each other but exist as a heterogeneous 
population with diverse myogenic potential; therefore not all the satellite cells are true 
muscle stem cells. This imprecision, in conjunction with the limited ability o f these 
cells to regenerate the muscle after their transplantation , due to survival ’ , 
immunological 33,35 and migration problems 36, had opened a debate whether or not the 
satellite cells should be considered stem cells. The formal proof of satellite cells being 
true stem cells was supplied only lately, by experiments that demonstrated their ability
11
to self-renew, repopulate irradiation-depleted muscles and regenerate the muscle greatly
37
The confusion concerning the stem cell capacity of satellite cells has also been 
caused by the inadequate isolation methods used. Traditionally, the whole muscles were 
dissected and enzymatically disaggregated, leading to cell cultures containing not only 
satellite-cell-derived myoblasts, but also other myogenic cells and fibroblasts. Since the 
mid 1980s, a fine technique has been established, allowing the isolation o f satellite cells 
from single myofibers, their expansion and their study in vitro 38. This method does not 
avoid the problem of the internal satellite-cell heterogeneity, but at least prevents the 
interference from other populations. However, satellite cells exhibit best their myogenic 
potential and retain their stem-cell characteristics when they are isolated directly by 
flow cytometry sorting and immediately transplanted without any previous in-vitro 
manipulation39.
The combination of the above experimental systems has recently elucidated 
several aspects of the satellite-cell biology. In the absence of stimuli satellite cells are 
quiescent; but during normal growth or muscle regeneration, induced by exercise, injury 
or degenerative diseases, become activated and enter the cell cycle, giving rise to two 
different cell types, the daughter myoblasts and the daughter satellite cells. This 
asymmetric cell division has been recently demonstrated by the asymmetrical co­
segregation of the template DNA strand 40 and the membrane-associated cytoplasmic 
protein Numb 41, which had been previously related with cell-fate determination. 
Notably, the daughter satellite cells can return to quiescence and constitute a reservoir 
of stem cells for future use; while the resulting daughter myoblasts proliferate 
extensively and finally differentiate and fuse with the damaged myofiber or with each 
other, to repair or to create new muscle fibres, respectively 42.
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This step-wise process is strictly regulated by the temporal expression of a 
category o f transcriptional factors, called myogenic regulatory factors (Mrfs). They are 
proteins that contain a DNA-binding basic helix-loop-helix (bHLH) motif and they have 
been originally identified for their ability to induce the conversion of C3H10T1/2 
fibroblasts into myoblasts 43. More recently, another category of transcription factors, 
called paired box genes, has been associated with satellite cells. Specifically, Pax7 and 
Pax3 (paired box gene 3) that share high homology, are expressed by satellite cells. 
While Pax7 is the most useful marker o f quiescent satellite cells and is also transcribed 
by proliferating myoblasts, the synthesis of Pax3 is restricted only to satellite cells o f 
some muscle-types 44. Initially thought to be necessary for the myogenic specification 
of satellite cells 45, Pax7 was proven by later studies to be essential for their propagation
i i * • • • • • • 44 46 47and their maintenance via its anti-apoptotic activity ’ ’ .
Satellite cells in mitotic quiescence express the genes c-m et48, CD34, and Pax7 
45. The expression of Myf5 (myogenic factor 5) within the satellite-cell population 
(Pax7+ cells) is heterogeneous, since the 90% of the cells are Myf5+ and the resting 10% 
Myf5' 49; while the remaining Mrfs are not present. Interestingly, this heterogeneity is 
resulting from the asymmetric cell division of the Pax7+/Myf5' cells and the Myf5 
expression in the daughter cells is determined by their basal or apical location. 
Remarkably, the intramuscular injection of Pax7+/Myf5‘ and Pax7+/Myf5+ cells 
demonstrated that exclusively the Myf5' cells are able to reconstitute the satellite-cell 
pool in vivo, suggesting that the above cell populations should be considered true 
muscle stem cells and myogenic committed progenitors, respectively 49. However, 
asymmetric cell division has previously been described also for the Myf5+ cells 40,41, 
rendering unclear whether this event occurs prior or after the activation o f Myf5. 
Nevertheless, these two possibilities are not mutually exclusive, and it is probable that 
the asymmetrical cell division takes place in both cell types, implying a multi-level
hierarchical model of muscle stem cell lineage progression, similar to the one accepted 
forLT- and ST-HSCs (see section 1.1.1).
In spite o f the above discrepancy, it is recognised that the satellite cells, after 
their activation, start to transcribe the myogenic differentiation-1 gene (MyoD) and up- 
regulate Myf5, while they continue to express Pax7 48>50"53. Their proliferation leads to 
the creation o f a heterogeneous population, regarding their expression pattern for Mrfs 
and Pax7 and hence their functional characteristics 54. Two distinct subpopulations co­
exist: one slow-cycling55, of cells with round morphology56 that retain Pax7 expression 
but down-regulate MyoD, and a second one, o f "thick" cells 56 that continue to express 
MyoD. The former one (Pax7+/MyoD‘) does not differentiate but returns to the 
quiescent state and becomes the "reserve" cells, while the latter one (Pax7+/MyoD+) 
keeps on proliferating and is destined to terminally differentiate 50,57. Consequently, 
these latter affirmations suggest an additional possible mechanism for the self-renewal 
of satellite cells.
Notably, MyoD over-expression converts the reserve cell population to
7^ /differentiating cells, and MyoD'' primary myoblasts display reduced differentiation
58potential and their transition from proliferation to differentiation is delayed in vitro . 
In vivo, the muscle fibre formation in MyoD'A mice is delayed during muscle 
regeneration 59. Therefore, despite that MyoD appears early, it is probably more 
important for the differentiation of satellite cells. After several rounds of proliferation 
and once a sufficient number o f myoblasts is reached, the MyoD+ cells stop to 
proliferate and start to differentiate. This stage coincides with the down-regulation of 
Pax7 and the expression o f two more Mrfs, myogenin and Mrf4 (myogenic regulatory 
factor 4) 52,57,60,61. Following the expression o f these late Mrfs, early muscle 
differentiation genes, such as myosin heavy chain (MHC), myosin light chain (.MLC) 
and muscle creatine kinase (MCK), are transcribed. Finally, the late muscle
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differentiation proteins (e.g. dystrophin and 6 -sarcoglycan) that are necessary for the 
contractile function of the myofibers 42 are produced (Figure 6).
The developmental origin of satellite cells, like the most aspects of their biology, 
has been uncertain until very recently. Initially, transplantation studies of donor quail
somites into host chicken embryos had suggested that satellite cells have the same
62somitic mesodermal origin with all the embryonic, foetal and adult skeletal muscle . 
Nevertheless, later experiments with explants from the dorsal aorta or the somites 
(E9.5) resulted in the generation of myoblast clones only in the dorsal-aorta-derived 
cultures, while the somite-derived ones had a fibroblast-like morphology. These dorsal- 
aorta-derived round-shaped clones were able to differentiate to myosin positive cells 
and to participate in muscle regeneration after their intramuscular injection. In addition, 
satellite cells appear also in the Pax3'A and c-metA mice that lack the somitically- 
derived migrating myogenic progenitors. Although, these data indicated that the 
developmental source of satellite cells is not somitic, but endothelial and differs from 
the other myogenic cell lineages 63; it is now believed that the extent o f the non-somitic 
contribution is limited and does not represent a major source for satellite cells. Instead, 
recent quail-chick grafting experiments, showing that Pax7+ satellite cells originate 
from the dorsal compartment of the somite 64’65, and developmental studies, employing 
Pax3GFP/+ and Pax7iacZ/+ and double transgenic mice, re-proposed a common somitic 
origin for all the myogenic lineages, including the satellite cells 66. The above two 
hypotheses are not necessarily mutually exclusive and the heterogeneity in the satellite­
cell compartment could also be explained by the presence o f two distinct cell 
populations with separate origins (Figure 7).
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Figure 5. Anatomical position of satellite cells .
(a) Electron microscopy reveals the anatomical position of satellite cells in vivo. A 
satellite cell (SC) is located in the sublaminal space, between the membrane of the fibre 
and the basal lamina as indicated by the arrowheads and arrows, respectively. Adjacent 
to it, a myonucleus (MN) within and at the periphery of the myofiber can be observed.
(b) X-gal staining of a single muscle fibre, isolated from a Myf5nhc7y+ knock-in mouse, 
reveals several Myf5^ (satellite) cells attached on it (day 0). Three days after their 
isolation (day 3), activated Myf5+ satellite-cell-derived cells are found detached from 
the fibre.
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68Figure 6. Temporal expression of myogenic marker genes by satellite cells .
CD34 and Pax7 are expressed in all the quiescent satellite cells; while the expression of 
Myf5 is heterogeneous, as revealed by the usage of a knock-in (Myf5nIacZ/T) mouse that 
produces S-galactosidase under the control of the Myf5 promoter. Activation coincides 
with Myod synthesis, which becomes permanent in contrast to Pax7 that is down- 
regulated during differentiation and Myf5 that is detected until the early stages of 
fusion. The expression of myogenin starts at the beginning of the differentiation and 
afterwards never ceases. MLC, as shown by the activation of the MLC promoter in the 
MLC3Y-nlacZ-E transgenic mice, and other structural proteins are detectable at the late 
differentiation.
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Figure 7. Developmental origin of satellite cells 69.
The two possible origins of satellite cells are schematically represented. According to 
the first one, the somite (S) gives rise to all the myogenic progenitors (red cells), 
including the migrating cells that will constitute the satellite-cell compartment in the 
adult mouse. Other reports suggested that satellite cells derive from muscle precursors 
(green cells) located in the dorsal aorta (DA). However, it cannot be excluded that the 
DA-derived precursors themselves originate from the somite (red cells) and 
subsequently generate the quiescent satellite cells (yellow cells). Overall, the data 
convincingly demonstrate that the myogenic progenitors, with satellite-cell behaviour, 
can be isolated both from the somite and the dorsal aorta. Indeed, it is probable that the 
satellite cell pool has a mixed source that could explain its heterogeneity.
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1.1.2.2 Non-satellite muscle-resident myogenic progenitors.
In addition to the satellite cells several other muscle-resident myogenic 
progenitors have been identified. One of them is the side population (SP) cells that are 
defined for their ability to actively exclude the hoechst 33342 fluorescent dye. These 
cells cannot differentiate into myocytes in culture alone, but proliferate in response to
7fi 7fl 71muscle injury , become specified to myogenesis in co-culture with myoblasts ’ ’ or 
C2C12 cells 72 and differentiate when exposed to Matrigel matrix 73. Intravenous 
injection, in dystrophic mice, o f muscle-derived SP (ms-SP) cells that are Scal+/CD45' 
/c-kif, although this phenotype was contradicted by later studies (see below), 
demonstrated that they can incorporate into the muscle fibre and express dystrophin 74. 
This ability was also confirmed by other studies that employed intramuscular 70>71>73 or 
intravenous 72 injection o f ms-SP cells in regenerating or dystrophic mouse muscles, 
respectively.
The muscle-resident CD45+/Scal+ and CD457Scal+ cells are also increased and 
proliferate during muscle regeneration 15, and display in-vivo myogenic potential with
7 £\low frequency and high frequency, respectively . The latter cell population can 
differentiate in culture alone 76,77, while CD45+/Scal+ cells cannot and need to be 
induced by different factors like muscle regeneration, co-culture with myoblasts, 
ectopic expression of Pax7 or activation of the Wnt signalling pathway by LiCl
7 ^ H (l 7 0
treatment ’ ’ , calling to mind the self-insufficient myogenesis of ms-SP cells. This
similarity, between the muscle-resident CD45+/Scal+ and the ms-SP cells, indicates a
link between the two cell populations and indeed, this case cannot be excluded, since
the CD45 and Seal phenotype of the muscle-resident SP cells is controversial.
Although it had been initially reported that they express Seal but not CD45 and c-k it74;
nowadays it is generally accepted that they comprise a heterogeneous cell population,
including mainly CD45'/Scal+/c-kif cells but also Seal', c-kit+ and CD45+ cells and all
19
the possible combinations o f cell subpopulations 65,71,73,74’79"81, making any attempt to 
compare studies investigating muscle-resident SP cells and CD45+/Scal+ cells chaotic. 
Nevertheless, both o f them lack an intrinsic and signal-independent myogenic potential, 
indicating the importance o f the microenvironment for their myogenic differentiation.
Muscle progenitors have also been isolated by pre-plating muscle preparations 
and subsequent flow cytometry sorting for the CD34 and the Seal markers. These cells, 
termed muscle-derived stem cells (MDSCs), should be distinct from satellite cells, since 
the latter ones are traditionally thought to be negative for Seal 45,71,82, although rare 
satellite cells expressing Seal have been detected 83. However, MDSCs can be found 
within the basal lamina and they spontaneously differentiate in myocytes and myotubes
0  4 Q C  Q A  O/T
in vitro . Their intrarterial or intramuscular ’ injection, in naturally occurring 
mutant mice lacking the dystrophin gene (mebe mice), demonstrated that they can 
contribute to the myofiber formation and express dystrophin.
A population of myogenic cells, which is certainly worthy mentioning for its
potential clinical application, are the mesoangioblasts. These cells were initially isolated
from the aorta of quail and mouse embryos, and their transplantation into chick embryos
demonstrated their mesodermal multipotency, giving rise to chondrocytes and
haematopoietic cells and contributing to the generation of vessels, bone and last but not
least to skeletal and cardiac muscles 87. Nowadays, mesoangioblasts can be also isolated
from the vessels of the adult mouse 88, dog 89 and human90,91 muscles, and therefore are
also called vessel-associated stem cells. RT-PCR analysis revealed the expression of
CD34, Flkl and c-kit but not Myf5 and MyoD from freshly isolated mouse cells.
Importantly, these stem cells can be expanded in vitro and differentiate into adipocytes
and osteoblasts in culture alone; while co-culture with myoblasts, cardiomyocytes or
BM cells is needed for their differentiation into myocytes, cardiocytes or
haematopoietic cells, respectively 87. Their intrarterial injection in 6 -sarcoglycan null
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mutant mice resulted in 5 -sarcoglycan+ muscle fibres with improved morphology and
functional properties, suggesting that they can regenerate the muscle at therapeutic
88levels . This ability was increased, enhancing their migration into the muscle tissue, 
using a treatment with stromal derived factor-1 or tumour necrosis factor 6 (TNFS) or 
ectopic expression of 6 4-integrin 90. Recently, Sampaolesi and colleagues reported that
the transplantation of mesoangioblasts in dystrophic dogs improved the function and the
80morphology of their muscles . This last report in conjunction with the availability of 
these cells in humans 90,91 renders them a promising approach for the treatment of 
human dystrophies.
The relationship between the muscle-derived non-satellite myogenic progenitors 
and satellite cells is still unclear. Satellite cells, isolated from single myofibers, can 
generate myogenic but not haematopoietic clones, in vitro 71. Conversely, the muscle- 
derived SP and CD45+/Scal+ cells cannot give rise myoblast clones but have in-vitro 
and in-vivo haematopoietic potential (see above and section 1.2.2). Based on these 
functional characteristics, it is clear that satellite cells and the muscle-derived SP and 
CD45+/Scal+ cells are distinct cell populations. However, studies claimed that
77 7 A 71intravenously ’ or intramuscularly transplanted ms-SP cells can give rise to 
satellite cells, detected in vivo and in single muscle-fibre cultures. In addition, Seale and 
colleagues observed that in Pax7'/_ mice the muscle cells exhibit an increased 
haematopoietic potential 75 and the muscle-derived CD45+/Scal+ (ms-CD45+/Scal+)
cells, although raised in proportion, are impaired for myogenesis, and therefore they
)
deducted that the muscle-resident CD45+/Scal+ cells are a continuous source o f satellite
cells via a Pax7-dependent path 78. Although these evidences had supported a
hypothesis, according to which satellite cells are not the true muscle stem cells but they
are another intermediate cell type (like myoblasts) between a multipotent stem cell and
the terminally differentiated fibre; later studies confirmed that satellite cells are the true
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muscle stem cells, based on their massive capacity to regenerate the muscle and their 
ontogeny (see section 1.1.2.1). Most probably, several myogenic progenitors exist in the 
muscle, both inside and outside of the satellite-cell compartment; but at the moment 
there are sufficient evidence only for the stem-cell ability of satellite cells (see Table 2).
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^^ vCell Population 
Characteristic^ .
Satellite
cells
SP
cells
CD45+
/Scal+
CD45'
/Seal*
CD34+
/Scal+
Meso­
angioblasts
Myogenic clones 
forming ability
+ + +
Differentiation in 
culture alone
+ + +
Differentiation in 
co-culture with 
myogenic cells
N/D + + N/D N/D +
In vivo myogenic 
potential
+ + + + + +
Haematopoietic 
clones forming 
ability
+ + N/D
In vivo 
haematopoietic 
potential
+ + N/D +
Table 2. Myogenic and haematopoietic potential of muscle-resident 
stem/progenitor cells.
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1.2 Stem cell plasticity.
Cell plasticity and pluripotency are traditionally considered properties o f the 
embryonic stem cells. On the contrary, the adult stem cells are thought to be restricted 
in their differentiation potential to the characteristic progeny o f the tissue in which 
reside (see section 1.1). However, in the last years several reports suggested that adult 
stem-cell plasticity also exists (Figure 8). For example, neural cells contributed to bone 
marrow (BM) 92 and to muscle 93, muscle to BM 94 and pancreatic cells to liver 95. BM 
cells appear to show the highest level of plasticity, participating in the formation o f liver 
96, lung 97, skin 97, kidney 98, pancreas " , myocardium 10°, central nervous system (CNS) 
101 and skeletal muscle 102. In all cases, the differentiation o f stem cells into a non- 
canonical progeny is an exceedingly rare phenomenon, almost invariably associated 
with severe damage in the target tissue and often with a specific selective pressure. 
Despite the low frequency o f the phenomenon, these observations suggested that the 
traditional view of tissue-specific adult stem cells may need to be revised and that the 
adult stem cells may not act only locally but they might also be recruited and 
reprogrammed.
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Figure 8. Stem cell plasticity 103.
Schematic representation of the ability of adult stem cells to generate cell types different 
from the ones of the tissue in which reside. The traditional view of stem cell biology 
contends that the adult stem cells are committed to the lineage in which reside. This 
dogma alleges that their nuclei have undergone irreversible chromatin changes that 
forbid the activation of other non-tissue-related transcriptional programs. In the last 
years, several experiments have proven that the nuclear reprogramming of the adult 
stem cells, thanks to chromatin plasticity, is possible; although its extent remains to be 
defined.
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1.2.1 Bone Marrow-derived myogenesis.
The role of BM-derived cells in adult-muscle regeneration is probably the most 
extensively studied case of adult stem-cell potential plasticity. The phenomenon was 
initially described in experiments, where non-fractionated BM cells were injected into
damaged mouse muscles or muscle regeneration was induced in BM-transplanted mice.
102In both cases, BM-derived cells participated in the formation o f new muscle fibres 
Notably, the infrequency o f the event did not allow the correction of murine muscular 
dystrophy by BM transplantation, casting doubt over the very existence o f BM-derived 
myogenesis 104. However, numerous reports describing several methods o f cell delivery 
(BM transplantation, intramuscular injection or even parabiosis) and induction of 
muscle regeneration (cardiotoxin, myotoxin injury or long-term exercise) confirmed its 
occurrence 105-117. This phenomenon is not well understood and there is still the need to 
investigate the nature of the BM subpopulation responsible for the event, the migration 
of these cells to the skeletal muscle, the existence o f a myogenic program that regulates 
the whole process and the ability o f the BM-derived nuclei located in the myofiber to be 
reprogrammed.
1.2.1.1 Characterisation o f the Bone Marrow subpopulation responsible for  
the phenomenon.
The identification o f the BM subpopulation, which can participate in muscle 
regeneration, is probably the best-studied aspect of BM-derived myogenesis. BM 
consists o f two major and separate cell compartments, the stromal and the 
haematopoietic cells that can both contribute to the muscle fibre formation and are 
easily distinguished by the panhaematopoietic marker CD45. The stromal-derived 
mecenchymal stem cells (MSC) do not express the haematopoietic markers CD45 and
26
CD34 and exhibit increased adhesive properties, in contrast to the haematopoietic cells, 
allowing their isolation from mouse and human BM.
The MSCs are fibroblast-like cells, multipotent 118 and can differentiate in 
muscle in vitro, as shown by their co-culture with myoblasts 119 or C2C12 cells 120, or 
culture in conditioned medium prepared from injured muscle 121. In addition, their 
injection into regenerating 120 or dystrophic 119 mouse muscles resulted in their 
incorporation into the muscle fibres and expression of dystrophin, demonstrating their 
ability to participate in muscle regeneration and to express muscle-late-differentiation 
genes in vivo. The activation of the Notch signalling in the BM-derived MSCs makes 
them potent myogenic progenitors. Most of the MSCs, ectopically expressing the 
intracellular domain of Notch, differentiated in Pax7+/MyoD+/myogenin+ myocytes and 
myotubes in vitro. Following intravenous or intramuscular injection, they regenerated 
the muscle and gave rise to Pax7+ cells located in the sublaminal space, strongly 
suggesting that they become satellite cells 122.
A pluripotent subpopulation o f MSCs, termed multipotent adult progenitor cells 
(MAPCs) has been also isolated 123, using a 3-week culture period and exclusion o f all 
the remaining haematopoietic cells (CD45+ and T erll9+ cells). Like ES cells (see 
section 1.1), MAPCs have the remarkable ability to contribute to most somatic tissues, 
including the muscle, following their transplantation into early blastocysts 124.
The haematopoietic cells are also able to contribute in muscle regeneration, but 
in contrast to MSCs they have the additional ability to circulate. Transplantation o f  
single HSCs (BM-derived CD45+/Scal+) or BM-derived CD45' cells has revealed that 
exclusively the haematopoietic subpopulation (CD45+) contains circulating BM cells 
with potential myogenic activity and that one single HSC is enough to sustain the BM 
contribution to skeletal muscle 106. Similar results were obtained by the transplantation 
of a single BM c-kit+/Lin'/Scal+ (HSC) c e ll125 or BM SP cells 74, which are purified for
27
their ability to exclude the Hoechst 33342 dye, are enriched for HSCs (CD45+/Scal+/c- 
kit+/lin' cells) and have been also detected in the muscle tissue (see sections 1.1.2 and
1.2.2). These findings, supported by numerous later studies 109’1H>1265 demonstrated that 
BM-derived myogenesis, following BM transplantation, results from the incorporation 
of haematopoietic cells into the muscle fibre and not from the differentiation of 
mesenchymal stem cells. However, the above experiments did not clarify if HSCs 
themselves or one o f their daughter lineages fuse to the muscle fibre.
More recently, the intramuscular injection of several haematopoietic cell 
subpopulations, based on the expression of the cell surface markers CD45, c-kit, Seal 
and other haematopoietic lineage markers, has allowed a detailed characterization o f the 
haematopoietic cells that can participate in muscle regeneration. Importantly, none of  
the mature lymphoid or myeloid populations were able to contribute to myofibers 
formation, but fractions containing HSCs and myeloid progenitors readily incorporated 
into the muscle fibres, suggesting that BM-derived myogenesis is due to the plasticity of  
haematopoietic stem/progenitor cells 107. This notion was also strengthened by 
concurrent studies, where BM-derived SP/CD45+/M acllow cells (early myeloid 
precursors) but not SP/CD45+/M aclhlgh (mature myeloid cells, macrophages) cells, 
isolated from the injured muscles of BM transplanted mice, were able to contribute to 
myotubes formation in co-culture with myoblasts 110 (see Table 3).
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'^Cell Population 
Characteristic^^
MSCs MAPS HSCs CMPs Mature
haematopoietic
cells
Myogenic clones 
forming ability
Differeniation in 
culture alone
Differeniation in 
co-culture with 
myogenic cells
+ + + +
In vivo myogenic 
potential
+ + + +
Ability to circulate - - + + -
Table 3. Myogenic potential of t le BM-derived ceIs.
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1.2.1.2 Migration o f Bone Marrow cells to the muscle.
The homing signals that recruit the BM cells, which incorporate into the 
myofiber, seem to be the same signals to which the cells of the immune system (e.g. 
white blood cells) respond during inflammation, since the percentage o f the BM-derived 
cells with myogenic potential (CD45+/Scal+ 127 and SP/CD45+ no) and the number of 
myofibers containing BM-derived nuclei 105,110,117,125 are readily increased after muscle 
damage. These observations are not surprising, since both cell types have a 
haematopoietic origin and reach the damage point shortly after injury. Additionally, 
some of these signals are also important for the regulation of satellite cells, showing that 
the processes of inflammation and regeneration are closely linked and currently it is 
impossible to dissect one from the other 42.
Insulin-like growth factor-1 (Igfl), which promotes the satellite-cell activation 
and proliferation and is upregulated during muscle regeneration 113, is o f particular 
interest. Its local production in muscles of transgenic mice, previously transplanted with 
BM SP cells and in which Igfl is under the control o f the muscle-specific promoter 
MLC, increases the muscle recruitment of the BM/donor-derived CD45+/c-kit+ and 
Scal+/c-kit+ cells 128 that are known for their myogenic potential. In more recent studies, 
Sacco and colleagues 113 used DNA electrotransfer, myoblast-mediated delivery or 
direct injection of Igfl, in order to achieve increased levels o f Igfl in muscles of  
previously BM-transplanted mice. This approach led to a considerable increase in the 
contribution of BM cells in the muscle-fibre formation, demonstrating the importance of 
Igfl in BM-derived myogenesis.
Contemporaneously, in-vitro migration assays showed that the migration o f BM- 
derived haematopoietic progenitors towards C2C12 or primary myoblast-derived
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myotubes is reduced by specific-treatment with an antibody blocking the receptor (Met) 
of the hepatocyte growth factor (Hgf), indicating that BM-derived cells migrate to the 
muscle in response to Hgf 129. Interestingly, this growth factor regulates muscle-cell 
migration from the somites to the limbs and to the diaphragm during mouse 
development130 and it is tempting to speculate that the BM-derived cells with myogenic 
potential follow the same path with the embryonic myogenic progenitors. Paradoxically, 
H gf is not expressed in the adult, both in healthy and injured muscles, as revealed by a 
gene expression profiling monitoring the process of muscle regeneration 131.
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1.2.1.3 Fusion versus Transdifferentiation.
Whether a specific myogenic program regulates BM-derived myogenesis, or it is 
simply the result of cell fusion is a controversial subject. The multinuclear nature of 
myofibers complicates any study that aims to investigate this aspect of the phenomenon, 
since fusion is the physiological manner to create muscle fibres and must take place for 
BM cells participating in muscle regeneration. Hence, the correct question is not if  
fusion occurs, but if a myogenic molecular program is activated within the BM-derived 
progenitors prior to their fusion to the muscle fibre. Intravenously transplanted BM cells 
were found between the plasma membrane of the muscle fibre and the basal lamina, 
where satellite cells (see section 1.1.2.1) are normally located, expressed satellite- 
specific genes, such as Myf5, c-met, Pax7, M-cadherin, or CD34 105,108,126,127 and 
proliferated in the damaged muscles 105. BM-derived cells isolated from the muscle of 
the recipient mice formed clones that expressed the satellite marker desmin, and were 
able to differentiate in multinucleated myotubes in vitro or fused with muscle fibres 
after their injection into tibialis anterior (TA) mouse muscles 105. Interestingly, the 
cultures of single muscle fibres from long-term BM-transplanted mice revealed the 
presence of BM-derived cells able to contribute to myotubes formation 126. All the 
above reports indicated that haematopoietic cells not only incorporate to the muscle 
fibres but more importantly they can give rise to satellite cells.
Sherwood and colleagues 127 confirmed the ability of BM cells to migrate and 
engraft in the sublaminal space, and express M-cadherin, and CD34; but in the same 
study they failed to reproduce the previously described intrinsic in-vitro colony-forming 
ability or myogenic differentiation (as assayed by MHC expression), displayed by these 
cells. In addition, the presence of BM cells within the basal lamina, expressing M- 
cadherin 114, and the occurrence of BM-derived satellite cells in single myofiber
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cultures 115 were also challenged, and it was suggested that haematopoietic cells 
participate in muscle regeneration by direct fusion without any previous specification to 
a muscle progenitor 106. These contradicting reports have fed a debate between 
transdifferentiation and fusion that remains open up today (Figure 9).
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Figure 9. Mechanisms of BM-derived myogenesis .
The molecular mechanism that regulates the participation of BM cells to muscle 
regeneration is the most interesting and controversial aspect of BM-derived myogenesis. 
Studies have claimed that certain BM-derived cells (cell with red nucleus) can become 
identical to the satellite cells (mononuclear cell with black nuclei), activating the same 
myogenic program used by the latter ones (e.g. Pax7 and Mrfs), and that the nuclei of 
these cells are completely reprogrammed (black nuclei). A second hypothesis predicts 
that these BM cells (cell with red nucleus) do not express any of the muscle-specific 
genes but simply fuse to the myofiber and therefore their nuclei are not reprogrammed 
(red nucleus into the fibre).
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1.2.1.4 Nuclear reprogramming.
Although the property of haematopoietic cells to incorporate into muscle fibres 
is now generally accepted, the ability of these cells to be reprogrammed prior or after 
the fusion event is unclear. The first study, in which BM cells isolated from a transgenic 
mouse that expresses LacZ under the muscle-specific MLC3F promoter were delivered 
by intravenous or intramuscular injection, reported that BM-derived nuclei located 
within the regenerating myoflbers were 6-gal+, indicating that these nuclei started to 
express muscle-specific genes 102. In addition, following reports claimed the synthesis 
of more muscle-specific proteins, like Myf5, myogenin 100 and dystrophin 74, by these 
incorporating cells, suggesting that a complete nuclear reprogramming is part of the 
process. However, further transplantation experiments of normal BM SP cells in S- 
sarcoglycan null mutant mice demonstrated that almost all the incorporated donor 
nuclei fail to express the 8-sarcoglycan (Sgcd) gene 109. In a similar experimental set­
up, using the dystrophin mutant mice, only 30% of the muscle fibres, containing donor- 
derived nuclei, were dystrophin+ 114. Interestingly, a study using in parallel dystrophic- 
and laminin-6 2-deficient mice as recipients revealed that BM transplantation restores 
the laminin-6 2 but not the dystrophin expression 116, indicating that the myogenic 
reprogramming can be gene-dependent. These data clearly put in doubt the ability of 
BM cells to be totally reprogrammed and therefore this aspect o f BM-derived 
myogenesis remains unclear.
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1.2.2 Muscle-derived haematopoiesis.
The relationship between the muscle tissue and the haematopoietic system has 
been strengthened by the observation that the former one contains cells that have HSC 
characteristics. Ms-SP cells not only participate in muscle regeneration (see section
1.1.2.2) but are also capable o f reconstituting the haematopoietic system upon their 
transplantation into lethally irradiated mice 74. A more detailed and long-term study 
showed that the muscle-derived haematopoietic cells are indeed true HSCs, since they 
could give rise to all the haematopoietic lineages (i.e. B-, T-lymphocytes and myeloid 
cells) both in primary and secondary recipient mice. Unexpectedly, the authors o f the 
same report, using competitive BM transplantations, claimed that the muscle tissue 
contains more HSCs than the whole BM (WBM). However, this experimental protocol 
included a culture period of the muscle cells prior to their transplantation, and this could 
enrich for HSCs, leading to an over-estimation of their frequency 94.In fact, fresh 
muscle preparations gave rise to haematopoietic colonies in vitro at a much lower 
frequency than the WBM 76,132.
The idea of muscle-derived non-haematopoietic cells with HSC characteristics 
was initially considered another proof of stem cell plasticity and this was temporarily 
supported by a report, in which CD45'/Scal+/c-kit' cells isolated from the muscle of 
neonatal mice contained long-term in-vivo haematopoietic potential 133. However, 
contemporaneous and later studies, fractionating muscle cells for the expression o f the 
HSCs surface markers CD45 and Seal, showed that exclusively the CD45+ cells can 
generate haematopoietic colonies in vitro 76,77,129. These CD45+ cells were both Scal+ 
and Seal', but only CD45+/Scal+ cells displayed multilineage haematopoietic 
engraftment in vivo 76. The CD45 expression and the haematopoietic potential of 
muscle-derived cells were also correlated by other studies, where muscle-derived
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SP/CD45+/Scal+ and SP/CD45+/Scal‘ cells (although at a lower frequency) produced
71 71 80 81haematopoietic colonies , while muscle-derived SP/CD45' cells did not ’ ’ . 
McKinney-Freeman and colleagues characterized further this population, showing that 
muscle SP cells expressing CD45 and c-kit are responsible for all the muscle-derived 
HSC activity 80.
Remarkably, parabiosis experiments demonstrated that the above muscle- 
resident SP/CD45+/c-kitdim, exhibiting multilineage and long-term haematopoietic 
repopulation capacity in vivo, could originate from the circulation 134. Interestingly, 
numerous BM transplantation experiments clearly demonstrated that the muscle- 
residing CD45+ cells are depleted by irradiation 129 and are subsequently replenished by 
BM cells 70’77’80’110’129’132> Analysis of the chimaeric mouse muscles showed that the
1 OQ 1 "XO 1 '2')cells bearing in-vitro ’ and in-vivo haematopoietic potential originated from BM. 
All these results strongly suggested that the haematopoietic potential exhibited by the 
muscle tissue is due to the BM-derived cells able to migrate and engraft to the muscle 
and it should not be attributed to the plasticity of the muscle-derived stem cells.
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2 Aims and Approach
The BM-derived CD45+/Scal+ cells are haematopoietic stem/progenitor cells 
that have the ability to circulate, migrate and engraft to the muscle tissue, and therefore 
they are o f particular interest. Notably, these cells retain their haematopoietic potential, 
as revealed both by in vitro and in vivo (see section 1.2.2) assays; but they also acquire 
myogenic potential, as shown by their ability to participate in muscle regeneration (see 
section 1.2.1.1). Whether, this latter remarkable ability is the result of the 
reprogramming o f BM-CD45+/Scal+ cells and the activation of a myogenic molecular 
program within these cells, remains controversial (see section 0). This study aims to 
clarify this aspect of the process, investigating the role o f the muscle microenviroment 
and key myogenic transcription factors.
We functionally characterized factors affecting BM-derived myogenesis,
employing reporter assays for muscle-specific genes, a comparative DNA microarray
analysis o f CD45+/Scal+ cells, deletion studies of myogenic transcription factors and
ectopic expression o f Pax7. Our study was focused on the myogenic transcription
factors Pax7, MyoD and Myf5. In order to evaluate their role in the myogenic potential
o f HSC-derived progenitors, we set up a BM-myoblast co-culture system, which allows
scoring the myoblast-clone-forming ability and the ability to undergo myogenic
specification and differentiation in vitro, and we also used BM transplantations to assess
BM-derived myogenesis in vivo. To this end we used labelled haematopoietic cells, in
which reporter genes are under the control of the MLC, the Myf5 or a chimeric
LTR/MCK promoter, or Pax7 and MyoD are missing. BM transplantation experiments
in PaxTA recipient mice were also used to avoid the competition by the recipient's
muscle stem cells and hence to fully explore the myogenic potential o f the
haematopoietic cells. In addition, a comparative gene expression profiling of the BM- or
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the muscle-isolated CD45+/Scal+ cells was employed to estimate more globally the 
ability of these cells to be reprogrammed and their relationship with the satellite cells. 
This analysis contributes to elucidate the role o f the muscle microenviroment and the 
specific myogenic pathways activated, during this process. Lastly, Pax7 was ectopically 
expressed in BM-CD45+/Scal+ cells to examine the capacity of this transcription factor 
to induce these cells to acquire satellite-cell-like characteristics and to increase their 
myogenic potential in vivo.
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3 Material and Methods
3.1 Reagents.
3.1.1 Chemicals.
All chemicals were obtained from FLUKA, Sigma Chemical Co. or Roche. 
Other chemicals used during the study were obtained from the following sources:
Protein markers Biorad
X-Ray film KODAK
Hydrolysed milk powder Nestle
Nitrocellulose for western blot Protran, Schleicher and Schuell
Nylon membrane for Southern Hybond-N, Amersham
Collagenase type II Worthington
OCT Tissue -Tek
paraformaldehyde Electron Microscopy Sciences
Table 4. Chemicals Source.
3.1.2 Radiochemicals.
P dCTP (Amersham).
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3.1.3 Solutions and buffers.
Buffer for flow cytometry analysis PBS containing 1 % v/v FBS
Fixation/Permeabilization buffer 25% v/v Fixation/Permeabilization concentrate 
(eBiosciences)
75% v/v Fixation/Permeabilization diluent 
(eBiosciences)
Permeabilization buffer 10% v/v Permeabilization buffer lOx 
(eBiosciences)
90% H20
lx  TBE for agarose gel 0.0089 M Tris Base 
0.0089 M boric acid 
0.0002M EDTA, ph8.0
lx  TAE for agarose gel (for 1 litre) 0.002 M Tris Base 
0.001 M N a Acetate 
0.1 mM EDTA, pH 8.0
100X Denhardts: lg  FICOLL 400 
lg  Polyvinylpropylene(PVP) 
lg  BSA (fraction V)
Up to 50 ml with water
20X SSC 350.6g NaCl
176.5g Citric acid, trisodium salt 
DNase free distilled water up to 2 litres
20X SSCP 88.2g Sodium citrate (trisodium salt)
140.3gNaCl
43.7gNa2HP04
12.7g Na2HP04.H20
DNase free distilled water up to 1 litre
Southern Hybridisation solution 
(for 20 ml):
6 ml 20X SSC
0.2 ml 100X Denhardts
10 ml deionised formamide
1 ml 10% w/v SDS
2g Dextran Sulphate
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2.8 ml of B.S256+probe
B.S256(10X) 16 mg polyA
16 mg polyC
400 mg yeast t-RNA
100 mg Salmon Sperm DNA
9 mg E. coli DNA
Western blot Solution A lOmM HEPES pH7.9 
1.5mMMgC12 
lOmM KC1,
0.5mM DTT
Western blot Solution B 300mM HEPES pH7.9 
1.4M KC1 
30mM MgC12
Western blot 5x loading buffer 300mM Tris Hcl pH 6,8 
10% SDS 
50% glycerol
25% beta-Mercaptoethanol 
0.04% of Bromo Phenol Blue
Western blot Transfer buffer (for 
1 litre):
3g Tris
14.4 g Glycine 
200 ml Methanol 
800 ml Water
Table 5. Solutions and buffers.
3.1.4 Restriction enzymes and bacterial strains.
All DNA modification enzymes, restriction enzymes and buffers were received 
from Roche or New England Biolabs. The DH5 bacterial strain (F’, hsdR17, rk-mk+, 
recAl, endAl) was used for all transformations, and grown in Luria Broth media (LB, 
Becton Dickinson) or Terrific Broth (TB, Becton Dickinson).
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3.1.5 Antibodies.
Isotype control antibodies, rat anti-mouse IgG (FITC, R-PE, 
PerCP or Tricolor conjugated)
PharMingen
Streptavidin comjugated with Tricolor Caltag Laboratories
Anti-mouse CD16/CD32 PharMingen
Anti-mouse CD3-PE (clone 17A2) PharMingen
Anti-mouse B220-PE and -APC (clone RA3-6B2) PharMingen
Anti-mouse Scal-PE (clone E13-161.7) PharMingen
Anti-mouse Scal-PE (clone E13-161.7) PharMingen
Anti-mouse CD45.2-PerCP-Cy5.5 (clone 104) PharMingen
Anti-mouse CD45.1-PE or -FITC (clone A20) PharMingen
Anti-mouse CD1 lb-PE and -APC (clone M l/70) PharMingen
Anti-mouse CD45-PerCP or-APC (clone 30-F11) PharMingen
Anti-mouse CD117-APC (clone 2B8) PharMingen
Anti-mouse IgG HRP-conjugated DAKO Cytomation
Anti-rabbit IgG HRP-conjugated DAKO Cytomation
Rabbit anti-GFP Molecular Probes
Alexa Fluor 488 donkey anti-rabbit Molecular Probes
Alexa Fluor 488 donkey anti-goat Molecular Probes
Alexa Fluor 594 donkey anti-mouse Molecular Probes
Goat anti-5 gal SantaCruZ
MHCf Novocastra
DYS2 Novocastra
Anti-human/mouse Pax3-PE R&D Systems
Anti-Pax7 DHSB
Anti-human histone H2B Abeam
Table 6. Antibodies list.
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3.2 Cell culture reagents.
3.2.1 Plastic ware.
All standard tissue culture plastic ware, (tissue culture flasks, roller bottles, 
collagen coated transwell apparatus, tissue culture plates) was obtained form Corning 
Costar.
3.2.2 Media.
IMDM Bio whittaker
HAM’s F-10 Sigma
RPMI 1640 Euroclone
BIT 9500 Stem Cell technology
DMEM Bio whittaker
Table 7. Culture Media.
3.2.3 Sera, Supplements and antibiotics.
Fetal Bovine Serum Euroclone
Trypsin Gibco Brl
L-Glutamine Gibco Brl
Penicillin/Streptomycin Gibco Brl
HEPES Gibco Brl
Polybrene Sigma
Beta-mercaptoethanol Sigma
Table 8. Sera, Supplements and antibiotics.
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3.2.4 Growth factors.
Recombinant human interleukin-6 (rhIL-6) R&D Systems
Recombinant human Flt-3 Ligand (Flt3-L) Pepro Tech, England
Recombinant murine Stem cell factor (mSCF) Pepro Tech, England
Recombinant murine interleukin-3 (mIL-3) PeproTech, England
Recombinant murine basic Fibroblast growth Factor (bFGF) Pepro Tech, England
Table 9. Growth factors.
3.2.5 Other.
Phosphate buffered Saline (PBS) was obtained from Euroclone.
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3.3 Mice.
C57BL/6/Ly-5.2, C57BL/6-Tg(ACTbEGFP)10sb (expressing eGFP
constitutively) and C57BL/6/Ly-5.1 mice were purchased from Charles River 
laboratories (Calco, Milan, Italy) and Jackson laboratories (Bar Harbor, Me.), 
respectively. Myf5nIacZ/+ 135 mice and MLC3F-«/acZ-E 136 mice, kindly provided by Dr. 
Tajbakhsh, and DmdFdx~4Cv 137 mice were bred in a C57BL/6 genetic background. To 
obtain a GFP transgenic mouse in which the nuclear-localising beta-galactosidase is 
under the control of the MLC3F or the Myf5 promoter, C57BL/6-Tg(ACTbEGFP)10sb 
heterozygotes were crossed with MLC3F-nlacZ-E homozygotes or Myf5nIacZ/+ mice,
I O O  1
respectively. MyoD null mutants and Pax7 heterozygote adult mice were bred in a 
mixed C57BL/6/-129/Sv genetic background. Pax7 heterozygotes were crossed with 
Myf5nlacZ/+ mice or MLC3>Y-nlacZ-E mice, and in the F2 generation Pax7~/~IMyf5nlacZ/+ 
mice and PaxTAfMLC3¥-nlacZ-E double transgenic mice were obtained. All 
procedures were approved by the Animal Care and Use Committee o f the Fondazione 
San Raffaele del Monte Tabor (Institutional Animal Care and Use Committee, licence 
number 299) and were communicated to the Ministry of Health and local authorities 
according to Italian law.
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3.4 Methods.
3.4.1 Pax7d Cloning and plasmid construction.
Total RNA from proliferating myoblasts was extracted using the TRI 
REAGENT (SIGMA), following the supplier's instructions. cDNA was synthesised 
using the SuperScriptTM III First-Strand synthesis system for RT-PCR 
(INVITROGEN). RT-PCR for cloning o f the Pax7d cDNA was performed with the 
following sets o f primers: Pax7-1F (5 ’-GGATTCGTCTCCAGCGTGTGCAGAAAT- 
3’), Pax7-1R (5’-ACCCTAGTAGGCTTGTCCCGTTTCCA-3’). The Pax7d cDNA was 
cloned into the pCR2.1 TOPO TA vector (INVITROGEN) according to supplier’s 
guidelines and it was partially sequenced to ensure that the Pax7d isoform was cloned. 
The resulting plasmid was digested with BamHI and was purified using the QIAquick 
PCR Purification Kit of QIAGEN. The linearised plasmid was digested with Xhol and 
the Pax7d cDNA was gel extracted using the QIAquick Gel Extraction Kit of QIAGEN. 
The lentiviral vector PGK.GFP 140 was digested with BamHI and Sail and the vector 
backbone was gel extracted. The Pax7d cDNA was inserted into the lentiviral vector by 
using the TAKARA DNA ligation kit Ver.l.
3.4.2 Polymerase chain reaction on genomic DNA.
DNA extraction from CFUs and WBM were performed, using the ChargeSwitch
Forensic DNA Purification Kit of Invitrogen, according to supplier's instructions and as
described in section 3.4.3, respectively. PCR reaction specific for the MCK.GFP vector
was performed with the following set of primers: MCKF (5’-
CTTTCCATGGCTGCTCGC-3’) and MCKR (5’-CGTGGTCTTAGGCTCTGTAC-3’).
For the PCR detection of the integrated PGK.Pax7 provirus, the following primers were
used: Pax7-2F (5'-TTGTGTCTCCAAGATTCTGTGCCGA-3') and Pax7-2R (5'-
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GCC ATACGGGAAGC AATAGC AT GAT-3'). The dNTP’s were obtained from Roche 
while the AmpliTaq gold polymerase enzyme, the PCR buffer and the MgCk solution 
were obtained from Applied Biosystems. The PCR samples were mixed with DNA 
loading dye and run on 1.2% w/v agarose gels in TBE buffer, containing Ethidium 
Bromide, and visualised on a UV lamp.
3 .4 .3  Southern blot analysis.
Genomic DNA was isolated from 1-5x106 cells using the QIAGEN QIAmp 
DNA mini Kit, following the manufacturers instructions. Nucleic acid concentration 
was determined using the 260/280nm absorbance measurements on a 
spectrophotometer.
For the creation of the probe, a 738bp DNA fragment corresponding to the RRE 
region, was obtained by digesting 20 g pRRL.sin-18. CMV.GFP.WPRE lentivector 
with A val and Muni. After running on a 1% w/v agarose gel, in TBE buffer, the band 
corresponding to the required DNA fragment was excised using a scalpel, and it was 
purified using the QiaexII DNA extraction kit from QIAGEN following the 
manufacturer's instructions. The concentration was measured and the probe was labelled 
as described below.
10 g of the genomic DNA was digested with Aflll concentrated enzyme over 
16-18 hours. The digested DNA was run on a 0.8% agarose gel in TAE buffer, 
containing ethidium bromide, overnight at 35 volts. The gel was photographed.
The DNA was denatured by incubating the gel in 0.2M NaOH, 0.6M NaCl for 1 
hour with one exchange of the buffer. The gel was then neutralised by incubation for 1 
hour in 1 M Tris HC1, pH7.5, 1.5M NaCl. Southern blot assembly was performed as 
described by Maniatis and colleagues 141 using Hybond Nylon filters from Amersham
48
(presoaked in distilled water and 10X SSC) overnight in 10X SSC. After blotting the 
filter was rinsed in 6X SSC and cross-linked using a Stratalinker.
The radioactive probe was mixed with B.S256, boiled for 10 minutes and 
quenched on ice, prior to adding to the hybridisation solution. This was performed to 
ensure that the denaturation o f the probe.
The filter was washed with 0.1X SSC, 0.5% w/v SDS at 65°C for 1 hour, 
exchanging the buffer twice, followed by an overnight incubation in pre-hybridisation 
solution at 42°C.
Pre-hybridisation solution:
5X Denhardt’s 
5X SSCP
50% deionised formamide 
The pre-hybridisation solution was removed and replaced with hybridisation
solution containing the radioactive labelled probe (2 x 106 dpm per ml). The filter was
incubated overnight at 42°C, followed by a 30-minute wash in 2X SSC, 0.1% SDS
(with one change) at room temperature and an one-hour wash at 55°C with 0.1X SSC,
0.1% w/v SDS (with 2 changes). It was subsequently dried and exposed to KODAK
autoradiograph film for various times and the films developed.
Radioactive labelling was performed using the Roche Random primed DNA
labelling kit and the quick spin columns (to eliminate the unincorporated nucleotides),
following the manufacturer's instructions.
3.4.4 Poliacrylamide gel electrophoresis (PAGE) and western blotting.
15% denaturating PAGE gels were made following the published instructions
(Maniatis, Fritsch et al, 1982), and were assembled on the Biorad miniprotean II gel
apparatus following the manufacturer's recommended instructions. 1-5x106 cells were
lysed in 100 1 of solution A for 10 minutes on ice. 3 pi Triton X-100 10% were added
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and the samples were centrifuged at 11.000 rpm for 1 minute at 4°C. The supernatant 
was collected and 11 pi o f solution B were added. The samples were centrifuged at
11.000 rpm for 1 minute at 4°C. The supernatant was collected and the protein 
concentration was determined using the BIORAD Protein Assay solution, following the 
instructions recommended by the manufacturer. Twenty illigrams o f the lysate were 
mixed with 5 1 o f 5-fold concentrated loading buffer, containing beta-
mercaptoethanol, and the resulting mixture was loaded into the well of the PAGE gel. 
The gel was run in Tris-Glycine buffer (27.9 g glycine, 6 g Tris, dissolved in 1 litre of  
water), containing 0.1% v/v SDS, at 40V, until the Bromo Phenol Blue dye had run out 
of the gel. As a molecular weight marker, 4 1 of the Rainbow marker (Biorad) were
used. Nitrocellulose membranes (Scleicher and Schuell) cut to the same size as the 
PAGE gel were pre-soaked in transfer buffer.
Blotting was performed using the Biorad Semidry Transfer Cell, assembled 
following the manufacturer's instructions. Upon assembly, the transfer was performed 
for 30 minutes at 15 volts at room temperature.
After the proteins had been transferred, the membrane was blocked in PBS
containing hydrolysed milk (5% w/v) for 60 minutes. The anti-Pax7 (dilution: 1/1000,
DHSB) and the anti-H2B (dilution: 1/20000, Abeam) antibodies (sc-21757, Santa Cruz
Biotechnology) were added to the blocking reaction incubated with agitation for 1 hour
at room temperature. The membrane was washed three times with PBS/0.05% v/v
Tween 20, and fresh blocking solution containing the polyclonal goat anti-mouse IgG
Horseradish Peroxidase (HRP)-conjugated antibody (DAKO Cytomation) and the
polyclonal goat anti-rabbit IgG Horseradish Peroxidase (HRP)-conjugated antibody
(DAKO Cytomation) at a 1 in 5000 dilution were added to the membrane. Incubation
was performed for one hour at room temperature with agitation. The membrane was
washed as before and the peroxidase activity was measured using the commercially
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available ECL kit (Amersham) following the recommended instructions. The membrane 
was exposed to KODAK autoradiograph film and it was developed.
3.4.5 Transformation of bacteria and bacterial and plasmid DNA 
preparations.
DNA to be transformed was mixed with 100 1 o f competent DH5 cells 
prepared specifically for the heat shock mediated transformation method (Maniatis, 
Fritsch et al, 1982). The mix was incubated on ice for 20 minutes, then 1 minute and 
45 seconds in a waterbath at 42°C, and then returned to the ice for further 10 minutes. 
The mix was then added to 1 ml of LB media and incubated at 37°C with agitation for 
one hour. The bacteria were then plated onto LB agar plates, containing the required 
antibiotic resistance and were placed overnight in a 37°C incubator. The following day, 
colonies were picked and placed into 1.5 ml of LB media containing antibiotics, and 
were grown overnight with agitation at 37°C. The small bacteria preparations were used 
for small or large-scale DNA preparation as required.
Small amounts o f plasmid DNA were purified from bacteria, for restriction 
analysis, using the GenElute Plasmid Miniprep kit (Sigma). We isolated plasmid DNA 
using the High purity Plasmid Megaprep system kit from Marlingen following the 
supplier's instructions.
3.4.6 Generation of Lentiviral vectors.
Viral stocks pseudotyped with the vesicular stomatitis G protein (VSV-G) were 
prepared by transient co-transfection of 293T cells using a three-plasmid system (the 
transfer vector, the pCMVpR8.74, encoding for Gag, Pol, Tat and Rev, and the pMD.G 
plasmid encoding for VSV-G). Moreover, a fourth plasmid for the synthesis of the Rev
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protein under the control of RSV promoter (pRSV.Rev) was added in order to increase 
the level of the unspliced viral RNA to be packaged.
Transfection of DNA using Calcium phosphate precipitation:
1. 9x106 293T cells were seeded in a 15 cm dish, approximately 24 hours before 
transfection in IMDM, 10%FBS, Penicillin (25U/ml), Streptomycin (25U/ml).
2. The medium was changed 2 hours before transfection.
3. The plasmid DNA mix was prepared by adding 7 g ENV plasmid (pMD2- 
VSV-G), 16.25 g of Core Packaging plasmid (pCMVpR8.74), 6.25 g Rev- 
expressing plasmid (pRSV.Rev) and 25 g transfer vector per dish. The plasmid 
solution was made up to a final volume of 2.25 ml with O.IXTE/H2 O (2:1) in a 
50 ml polypropilene tube. Finally 250 1 of 2.5M CaCl2 were added to the mix.
4. The precipitate was formed by drop-wise addition o f 2.5 ml HBS (281 mM 
NaCl, 100 mM HEPES, 1.5mM Na2HP04) to the DNA-TE-CaCl2 mixture while 
vortexing at full speed. The precipitate was then added to the 293T cells 
immediately. High magnification microscopy of cells revealed a very small 
granular precipitate of the CaPi-precipitate plasmid DNA, initially above the cell 
monolayer, and after incubation in a 37°C incubator overnight on the bottom of  
the plate in the spaces among the cells.
5. The CaPi-precipitated plasmid DNA was allowed to stay on the cells for 14-16 
hours, after which the media was replaced with fresh media. The medium was 
discarded as infectious waste.
6. The cell supernatant was collected at 24 hours after the media exchange.
7. The cell supernatant was centrifuged at 1500 rpm, for 5 minutes and filtered 
through a 0.22 m pore nitrocellulose filter.
8. The conditioned supernatant was concentrated (see section 3.4.7).
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3.4.7 Viral concentration.
1. The virus-containing supernatant was concentrated by ultra-centrifugation at
50,000 x g (19,500 rpm in SW28 rotor) 2 h at RT.
2. The supernatant was discarded by decanting
3. The final pellets were re-suspended in a very small volume (1/350 o f the starting 
volume of medium) of sterile PBS.
4. The aliquots were pooled in a small tube and rotated on a wheel at 4°C for 1 h 
(10 rpm).
5. The virus was divided into small aliquots (20-50 pi) and stored at -80°C and the 
viral titre was determined after freezing.
3.4.8 Titration of Lentiviral vectors.
3 8Serial ten-fold dilutions of the viral stocks were prepared (from 10' to 10'). 
2x105 HEL cells were re-suspended in 1 ml of each serial dilution and plated in a well 
of a 24-well plate. Polybrene was added to each well (final concentration: 8pg/ml). The 
infected HEL cells were incubated for 24 hours at 37°C in a 5% CO2  incubator and the 
day after transduction the cells were washed with 1 ml of PBS and resuspended in 1 ml 
of fresh medium.
For the GFP- and the Pax:7-expressing vectors, on day 5 after the transduction 
the cells were collected in flow cytometry tubes, washed with 2 ml o f PBS and 
centrifuged at 1500 rpm for 5 min at RT. The supernatant was aspirated and the pellets 
were re-suspended in 1 ml of PBS 1% FBS, FACS analysis for GFP or Pax7 expression 
was performed and the titre was calculated as follows:
TU/ml= (% of GFP+ cellsVlOO x number of plated cells ("2x105) 
Transduction volume x viral vector dilution
TU=transducing unit.
53
For the MCK.GFP vector, on day 20 after transduction, the infected cells were 
collected, their DNA was extracted and the transduction efficiency was evaluated by 
quantitative real-time polymerase chain reaction (qPCR) as described in sections 3.4.3 
and 3.4.9, respectively. The titre was calculated as described above for the GFP- and 
the Pax 7-expressing vectors.
Note: The MOI (multiplicity of infection) is defined as the fraction: Transducing units / 
number of cells to be infected.
3.4.9 Maintenance and transduction of stable cell lines.
Human erythroleukemic (HEL) cells were maintained in RPMI-1640 with 10% 
FBS. The 293T cell line was maintained in IMDM media and 10% FBS. All these 
media were supplemented with penicillin/streptomycin at 100 units/ml, and L-glutamine 
[2 mM]. The adherent cells (293T) were typically passaged at 1/5 to 1/20 dilutions 
(depending on experimental requirements.) twice a week by washing once in PBS, 
adding trypsin solution to the adherent cells, incubating for 3 minutes and then re- 
suspending in fresh media. The non-adherent cells (HEL) were passaged by simple 
dilution of the cells in fresh media (usually at 1/10 dilutions twice a week). The HEL 
and the 293T cell lines were transduced with viral supernatants at different MOI in the 
presence of 8 gg/ml of polybrene. All cells were maintained at 37°C in a humidified 
incubator with atmospheric 5% CO2 .
3.4.10 Quantitative PCR.
The average vector copy number per cell was measured by quantitative real-time 
polymerase chain reaction (qPCR). PCR was performed using primers and probe that 
anneal in the RRE sequence: RRE forward primer (5'-
TGAAAGCGAAAGGGAAACCA-3'), RRE reverse primer (5'-
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CCGTGCGCGCTTCAG-3') and RRE probe (5'-VIC-AGC TCT CTC GAC GCA GGA 
CTC GGC-MGB-3') (Applied Biosystems). Primers and probe complementary to the 
human GAPDH gene were used to normalize for the DNA content. The GAPDH 
primers were as follows: GAPDH forward primer (5-
ACC AC AGTCC AT GCC AT C ACT-3'), GAPDH reverse primer (5'-
GGCC AT C ACGCCAC AGCTT-3') and GAPDH probe (5'-TET-
CCACCCAGAAGACTG TGGATGGCC-MGB-3') (Applied Biosystems). MasterMix 
containing dNTPs, polymerase and buffer, was obtained from Applied Biosystems. The 
quantitative PCR was performed in a ABI 7900 Real Time PCR machine (Applied 
Biosystems).
3.4.11 Primary myoblast cultures and co-cultures.
Purified muscle cells were cultured (105 cells/ml) in HAM’s F-10 medium 
(Sigma) supplemented with 20% FBS and 5ng/ml bFGF (Peprotech), on collagen- 
coated dishes, after pre-plating for 1 hour in uncoated dishes. BM cells were isolated as 
described below and were cultured for 2 days in serum-free IMDM, containing BIT 
serum substitute, 50 ng/ml muSCF, 10 ng/ml muIL-3, 10 ng/ml huFlt-3L and 20 ng/ml 
huIL-6. The cultured BM cells or BM-derived cells sorted from the muscle for CD45 
and Seal expression were mixed with proliferating primary myoblasts at a ratio 1:1 and 
were seeded on collagen-coated wells of 6-well plates. The cell density was 4 x 104 
cells/well. The co-cultures proliferated in myoblasts proliferation media for 3-4  days 
and differentiated in DMEM supplemented with 5% horse serum for 2-3 days. For the 
sorted BM cells, CD45+ cells from the Myf5nlacZ/+ mice were put together with CD45' 
cells from the WT mice in their ratio in the whole BM. This process was repeated for 
the CD45', Scal+, Seal", c-kit+ and c-kif cells and the diverse sub-populations were 
subsequently co-cultured with myoblasts.
3.4.12X-gal staining and immunofluorescence.
For the X-Gal staining, the cultured cells were fixed with 0.2% glutaraldehyde 
and were incubated overnight at 37°C with 5-bromo-4-chloro-3-indolyl 5-D-galactoside 
solution. For the enumeration of regenerated myofibers, the TA muscles were isolated, 
fixed in 4% paraformaldehyde, cryoprotected in sucrose 5-20%, embedded in OCT and 
frozen in isopentane cooled in liquid nitrogen. The immunofluorescence staining was 
performed on 10- to 16-pm cryosections. In the case o f cultured cells, the fixation and 
the permeabilization were performed with 2% paraformaldehyde and 3% sucrose for 10 
minutes and 0.5% (v/v) Triton-X for 10 minutes, respectively. Subsequently, the 
samples were blocked for 1 hour with donkey serum and then incubated with the 
following primary antibodies: rabbit anti-GFP (Molecular Probes, 1/200), goat anti-bgal 
(SantaCruZ, 1/50), mouse anti-Pax7 (DHSB, 1/1000) and MHCf (NOVOCASTRA, 
1/40) for lhour at room temperature. Alexa Fluor 488 donkey anti-rabbit, Alexa Fluor 
488 donkey anti-goat and Alexa Fluor 594 donkey anti-mouse (Molecular Probes, 
1/500) were used for the secondary detection (45 minutes at room temperature) and 
Hoechst 33342 dye for the nucleus visualization. To rule out the possibility o f auto­
fluorescence mistaken for GFP, only myofibers positive for a length o f more than 150- 
pm were considered.
3.4.13Transduction of murine BM cells.
Murine BM cells were harvested from mice as described below and infected for
18 hours with viral stocks at an MOI of 100 or 50 in serum-free IMDM, containing BIT
serum substitute, 50 ng/ml muSCF, 10 ng/ml muIL-3, 10 ng/ml huFlt-3L and 20 ng/ml
huIL-6. The transduced BM cells were washed with PBS and plated at a density o f 0.2 x
105 cells/ml in methylcellulose medium that supports the growth o f murine
hamatopoietic colonies (see section 3.4.14). For the GFP-expressing vectors, the
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transduced BM cells were also grown in liquid culture in the same medium described 
above and were analysed by flow cytometry for GFP expression on day 5 after the 
transduction. For the MCK.GFP and the Pax 7-expressing vectors, single colonies were 
isolated 10-14 days after plating and the transduction efficiency was assessed by PCR 
screening o f CFCs using primers specific for each vector (see section 3.4.1).
3.4.14CFC assay.
BM and muscle-derived cells, purified as described below, were washed with 
PBS and plated at a density of 0.2 x 105 and 105 cells/ml, respectively, in 
methylcellulose medium that supports the growth of murine colonies, containing 
rmSCF, rmIL3, hIL6 and hrEPO (M3434, Stem Cell Technologies). For the assays of 
BM and muscle-derived cells, the colony number was assessed at day 10 and 8 after 
plating, respectively. For the lentivirally transduced BM cells, the single colonies were 
isolated 10-14 days after plating and the transduction efficiency was assessed by PCR 
screening of CFCs using primers specific for the vector (see section 3.4.2).
3.4.15Flow cytometry and cell sorting.
Muscle and BM cells were prepared as described below, resuspended in IMDM, 
supplemented with 10% FBS, at a density of 107 cells/ml and incubated with anti-CD 16 
antibody for 15 minutes at 4°C (Pharmingen, San Diego, CA) to block nonspecific 
binding to the Fc receptor. The purified cells were subsequently stained with the 
appropriate antibody (Table 6) for 45 minutes at 4°C. The unbound antibodies were 
removed by a final wash with PBS before the analysis on FACScan or FACSCalibur 
(Becton Dickinson, Mountain View, Calif.). The cells were sorted by flow cytometry by 
a double laser instrument (FACSVantage, BecktonDickinson) and the purity was close 
to 95%. The chimaerism in the bone marrow and the muscle was determined by staining
with anti-CD45.1 and anti-CD45.2 antibodies and it was calculated from the 
CD45.2/(CD45.1+CD45.2) ratio cell counts. All the BM-transplanted mice used, 
reached a chimaerism higher than 85%.
For the Pax7 intranuclear staining, the cells previously stained for the surface 
markers as described above were fixed and permeabilized with the 
Fixation/Permeabilisation solution of eBiosciences overnight at 4°C. The cells were 
subsequently re-suspened in Permeabilization buffer (eBiosciences) at a density o f 107 
cells/ml, re-incubated with the anti-CD 16 antibody and finally stained with an anti­
human/mouse Pax3-PE antibody (R&D Systems), able to cross-react also with Pax7, for 
45 minutes at room temperature.
3.4.16Magnetic enrichment of BM-Scal+ cells.
Murine Scal+ cells were purified from the total BM by staining the BM cells 
with PE-conjugated anti-mouse Seal antibody. The cells were washed with PBS (BSA: 
1% w/v) to remove the unbound antibodies and were magnetically labelled with anti-PE 
Microbeads (Milthenyi Biotech, Auburn, Calif.). Then the cells were loaded on a MS 
column and separated using the Mini MACS separator (Milthenyi Biotech, Auburn, 
Calif.). Both the positive and negative fractions were FACS analyzed to check the 
purity.
3.4.17Sacrifice of mice and BM and muscle cells isolation.
Mice were sacrificed by carbon monoxide inhalation and their femurs and tibias 
were removed by surgical procedure, the BM was obtained by flushing the bones with 
IMDM with 1% FBS using a syringe and a 22-gauge needle. After re-suspension, the 
cells were passed through a 40-pm cell strainer. The cell numbers were counted and the 
viability was assessed by trypan blue staining. For the isolation of muscle cells, the
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tibialis anterior and the quadriceps muscles were excised from transplanted mice. The 
bones and the tendons were removed and the muscle tissue was thoroughly minced and 
then digested at 37°C with 0.2% collagenase type II-filtered (Worthington) for 30 
minutes. The tissue was triturated briefly by using a 10-ml pipette and then passed 
successively through a 100-pm, a 70-pm and a 40-pm cell strainer (Falcon). The cells 
were collected by centrifugation, re-suspended in the appropriate medium and counted 
using ahaemocytometer.
3.4.18BM transplantations.
For BM transplantation experiments, six- to eight-week-old mice were used as 
donors or recipients. 2-3 million of BM cells were prepared as described above, washed 
twice in PBS, ensured to be a single cell suspension and suspended in 100 pi of 
physiological serum. The cells were taken up into a 1 ml syringe with low gauge needle 
(26Gx 1/2”) and transplanted via intravenous injection into six-week-old C57BL/6 or 
PaxTA recipients that had received 11 or 10 Gy of irradiation, respectively. Tail vein 
injection was performed, holding a high intensity lamp to the tail o f the mouse and 
waiting for the veins to become clearly visible. The needle was then gently inserted into 
the visible vein and the plunger very slowly depressed to inject the cells into the mouse. 
After successful completion of injection the mice were returned to their cages and 
neomycin antibiotic was included in the water supply to prevent bacterial infections.
3.4.19Muscle injury and isolation.
30 pi of cardiotoxin [0.1 mM] (Sigma) were injected into the TA and the 
quadriceps muscles using a 29G syringe. Mice were sacrificed from 4 days to 5 weeks 
after injury and the TA muscles were cryopreserved and used for immunofluorescence, 
or muscle-cell preparations were prepared as described above. The cells were counted
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using a haemocytometer, collected by centrifugation and re-suspended in the 
appropriate medium. They were subsequently used for flow cytometry sorting and/or 
culture, and X-gal staining or immunofluorescence imaging followed.
3.4.20Microscopy, statistics and bioinformatics.
All the samples were visualised using a 1X50 Olympus inverted microscope at 
room temperature and the pictures were acquired with a DS-L1 Nikon camera and 
processed with Adobe Photoshop CS version 8. All the statistical analyses were two- 
tailed tests and performed using GraphPad Prism version 4.00 for Windows (GraphPad 
Software, San Diego, USA). The frequencies and the errors represent mean values and 
errors of the means, respectively, unless otherwise stated. The gene expression data 
were analysed with the online Ingenuity Pathway Analysis system (Ingenuity Systems, 
www.ingenuitv.com) using the Ingenuity Pathway Knowledge Base as the dataset 
reference.
3.4.21 DNA microarray analysis.
CD45+/Scal+ cells isolated from the BM or the muscle were processed fresh and 
their RNA was extracted and treated with DNase 1, using the RNAqueous®-4PCR kit 
(Ambion) according to the manufacturer's instructions. The DNA microarray analysis 
was performed using the Affymetrix MOE430A Gene Chip arrays as previously 
described 142.
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4 Results
4.1 BM-CD45+/Scal+ cells undergo myogenic specification, 
differentiation and incorporation into muscle fibers in a 
Pax7-independent manner.
4.1.1 BM cells enriched for HSC surface markers are able to undergo 
myogenic specification, differentiate and contribute to myotube 
formation.
We set up a co-culture assay of BM cells and primary myoblasts to investigate 
the molecular mechanism underlying in BM-to-muscle transition and to assess the 
ability of BM cells to express muscle-specific genes, such as Myf5. Myf5 is an excellent 
marker of myogenic specification (see section 1.1.2.1), therefore we decided to employ 
a knock-in mouse (Myf5nlacZ/+), which produces the nuclear-localising 6-galactosidase 
(6-gal) under the control of the Myf5 promoter 135. BM cells derived from Myf5nlacZ/+ 
mice were co-cultured with unlabelled primary myoblasts. After 3-4 days of  
proliferation, X-gal staining was performed and 68 ± 24 (n=4) 6-gal+ cells were 
detected from 5 x 104 initially plated BM cells (0.13% ± 0,05%, n=4, Figure 10a and 
10b). This observation showed that certain BM cells are able to express Myf5, following 
co-culture with myoblasts. However, they never gave rise to myogenic clones, 
suggesting that these cells cannot proliferate or self-renew like Mj/J-expressing 
satellite-derived myoblasts do.
To ensure that the Myf5+ BM cells are derived from haematopoietic progenitors, 
BM cells were sorted for the HSC surface markers CD45, Seal, and c-kit. BM cells
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from Myf5nlacZ/+ and WT mice were sorted and subsequently combined in order to 
reconstitute the composition of WBM (see section 3.4.11). X-gal staining revealed that 
the cells sorted for CD45, Seal, and c-kit expressed Myf5 with a statistically 
significantly higher frequency than WBM (Friedman test: pO.OOOl); while hardly any 
8-gal+ cells were also found in the negative fractions at levels bellow the expected 
background of sorting cross-contamination (Figure 10c). These results demonstrate that 
BM cells enriched for HSC-surface markers can express the myogenic transcription 
factor Myf5 in co-culture with myoblasts.
To further verify the myogenic specification of BM-derived haematopoietic 
cells, we set out to demonstrate the expression of other muscle-specific genes. 
Therefore, we repeated the co-culture experiments using BM cells derived from a 
double transgenic mouse, in which the nuclear-localising 5-galactosidase is under the 
control of the MLC3F promoter and GFP is ubiquitously expressed (see section 3.3). 
MLC is an early muscle differentiation marker and previously has been reported its 
expression both before and after the formation of myotubes by myoblasts. This feature 
allowed us to monitor the expression of MLC at different stages of the co-culture. After 
differentiation and X-gal staining, single MLC-expressing (8-gal+) cells were found 
(0.11% ± 0.033%, n=8) demonstrating that BM cells can also express MLC as a 
myogenic marker in addition to Myf5 (Figure 11a and lib ). Interestingly, we also 
detected rare GFP+ myotubes (Figure 11c) containing 5-gal+ nuclei (Figure lid ), 
demonstrating that these BM cells can contribute to myotube formation (approximate 
frequency 0.01%) and that their nuclei continue to express MLC after fusion.
Furthermore, we decided to evaluate if  the BM-derived haematopoietic cells
expressing Myf5 during the proliferation phase were likely the same cells that finally
express MLC and differentiate. To this end, we exploited the known persistence o f Myf5
expression from myoblast to myotube 53 in a co-culture assay with BM of Myf5nlacZ/+
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mice. After spontaneous differentiation (i.e. no serum deprivation), 
immunofluorescence for the early myogenic differentiation marker MHCf and 5-gal 
revealed that certain BM-cells co-express MHC and Myf5 (Figure 12 a-d). Moreover, 
A^/5-expressing myocytes and myotubes were also found (Figure 12f and 12e). 
Notably, these BM cells expressed the above myogenic markers only in co-culture with 
myoblasts and never in culture alone, indicating that interaction with muscle cells is 
required. Overall, these findings strongly suggest that HSC-derived myogenic 
progenitors do not only undergo myogenic specification (Myf5 expression) but also 
differentiate (MLC and MHC expression) and contribute to the myotube formation in 
vitro (although at a much lower frequency than the first two events).
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Figure 10. BM cells enriched for HSC surface markers occasionally express Myf5 
in co-culture with myoblasts.
(a-b) BM cells isolated from Myf5nlacZ/+mice were co-cultured with unlabelled primary 
myoblasts. After 4 days of proliferation, X-gal staining and bright field microscopy 
revealed several 6 -gaf (j^/5-expressing) cells (0.13% ± 0.05%, n=4). (c) Different BM 
sub-populations were co-cultured with myoblasts demonstrating that BM cells enriched 
for HSC markers express Myf5 at a higher frequency than WBM. The error bars 
represent the standard error of the means of six different experiments and the p value 
was calculated using a Friedman test.
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Figure 11. BM cells can differentiate and contribute to myotubes formation in co­
culture with myoblasts.
(a-b) BM cells isolated from GFP/MLC3¥-nlacZ-E mice were co-cultured with 
unlabelled primary myoblasts. After differentiation, X-gal staining and bright field 
microscopy revealed few S -gaf (MLC-expressing, differentiated) cells (0.11% ± 0.033, 
n=8). (c-d) GFP+ myotubes (panel c: fluorescence microscopy) were also detected 
synthesizing nuclear-localized beta-galactosidase (panel d: bright field miscroscopy).
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Figure 12. Step-wise myogenic differentiation of BM-derived myogenic progenitors 
in co-culture with myoblasts.
BM cells isolated from Myf5n]ac7J+ mice were co-cultured with unlabelled primary 
myoblasts, (a-c) After spontaneous differentiation, the MHCf and b-gal 
immunofluorescence revealed M H Cf and Myf5 co-expression (A: b-gal, B: MHCf, C: 
Hoechst and D: electronic merge), (f-e) X-gal staining and bright field microscopy 
allowed the visualization of 6-gal+ (A/y/5-expressing) myocytes (f) and myotubes (e).
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4.1.2 BM-derived CD45+/Scal+ cells isolated from regenerating muscle 
can be specified to myogenesis.
In order to demonstrate the capacity of BM-CD45+/Scal+ cells for myogenic 
specification in vivo, Myf5nlacZ/+/C57BL/6-CD45.2 mice expressing GFP constitutively 
were used as donors for BM transplantation in lethally irradiated C57BL/6-CD45.1 
mice (see section 3.4.18). This CD45 isoform mismatch allowed us to distinguish 
between the haematopoietic cells derived from the donor and the residual recipient cells 
in chimeric mice, in which the bone marrow is GFP/Myf5nlacZ/+ while the rest of the 
tissues are not labelled. After complete reconstitution of the haematopoietic system (six 
weeks), the right quadriceps and the tibialis anterior (TA) muscles were injected with 
cardiotoxin (ctx) to induce muscle regeneration. Four days after ctx injection, the mice 
were sacrificed and their injured muscles were removed and prepared for sorting by 
flow cytometry (Figure 13a). GFP+ (BM-derived), CD45+/Scal+ (haematopoietic) cells 
were sorted and co-cultured with unlabelled myoblasts and once again Mj/5-expressing 
(6-gal+) cells were detected (0.02%± SD=0.008%, n=3), using X-gal staining (Figure 
13b). Hence, certain BM-derived haematopoietic (CD45+/Scal+) cells isolated from 
injured muscle can also express Myf5, as it had been initially shown for haematopoietic 
cells isolated from BM.
Additionally 3-5 weeks after injury, GFP+ myofibers (52 ± 1 0 ,  n=6) were 
observed in TA muscles of transplanted mice (Figure 13c). However, this result did not 
unequivocally demonstrate the hematopoietic origin o f the BM cells that incorporate 
into muscle fibres, since the experiments were performed by transplanting WBM. To 
address this issue, we isolated by cell sorting the CD45+ and the CD45' fractions of the 
BM derived from C57BL/6-GFP and C57BL/6 mice. Lethally irradiated C57BL/6- 
CD45.1 mice were transplanted with either GFP+/CD45.2+ and CD45.27GFP' cells or
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GFP+/CD45.2' and CD45.2+/GFP' cells in proportions identical to the total BM. Six 
weeks after BM transplantation, TA muscles of transplanted animals were subjected to 
ctx injury and 3 weeks later were analyzed. Several GFP+ myofibers were scored in TA 
muscles o f mice transplanted with the CD45+/GFP+ cells (n=6), whereas no GFP+ 
myofibers were found in the TA muscles of the mice transplanted with the CD45'/GFP+ 
cells (n=6), confirming the notion that only the cells from the haematopoietic 
compartment o f the donor BM are able to participate to muscle regeneration, following 
BM transplantation.
To evaluate the contribution of donor-derived cells to the haematopoietic 
progenitors seeded in muscle, we further transplanted lethally irradiated C57BL/6- 
CD45.1 mice (n=18, from 3 independent experiments) with BM cells isolated from 
transgenic C57BL/6-CD45.2-GFP donors. Six weeks after BM transplantation, a 
clonogenic assay of 105 cells derived from the muscle of the recipient mice revealed a 
mean o f 12 ± SD=2 (n=3) GFP+ CFUs (colony forming units) out of 14 ± SD=2 (n=3) 
CFUs/105 cells. These results reflect the high level of donor chimaerism, also shown by 
flow cytometry analysis, and suggest a BM origin for the muscle-resident 
haematopoietic cells in general. Additionally, the lethal irradiation used for BM 
transplantation depleted the ms-CD45+/Scal+ cells (Figure 14a) and the donor BM- 
derived cells replenished this population after BM transplantation (Figure 13a and 
Figure 14b), further supporting this hypothesis. Morphological analysis showed that the 
donor-derived haematopoietic cells present in the muscle give rise to all the different 
types of haematopoietic colonies (e.g. Figure 13e), although the frequency was a tenth 
of that observed in CFU assays of progenitors isolated from WBM.
In order to assess whether the haematopoietic potential o f BM cells, shown in
healthy muscle, would be affected by the muscle injury; we transplanted lethally
irradiated C57BL/6-CD45.1 mice (n=35 from 3 independent experiments) with BM
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cells from C57BL/6-GFP donors and induced muscle regeneration by ctx injection. 
When we plated in methylcellulose 105 mononucleated cells from the injured muscles, 
no typical haematopoietic colonies were observed. Both host- and donor-derived (GFP+) 
cells gave rise to mixed colonies, containing both round- and fibroblast-shaped cells 
(Figure 13d). Similar results were obtained by plating 2x104 sorted GFP+/CD45+/Scal+ 
cells in the methylcellulose media. These data show that the haematopoietic potential of 
the BM-derived cells while maintained in healthy muscle, it is highly impaired from 
injury, suggesting a change of cell fate during muscle regeneration.
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Figure 13. BM-CD45+/Scal+ cells isolated from regenerating muscle can be 
specified to myogenesis.
(a) Flow cytometry analysis of injured muscles from mice transplanted with 
GFP!Myf5nlacZ'" donor cells (top panel: forward scatter and side scatter; middle panel: 
CD45 and Seal expression; lower panel: GFP expression on CD45+/S cal+ cells), (b) 
BM-CD45+/Scal+ cells isolated from injured muscle of mice transplanted with 
GFP/Myf5nlacZ/+ donor cells expressed Myf5 in myogenic co-culture, as it was detected 
using X-gal staining and bright field microsopy. (c) BM cells also participated in 
muscle regeneration in vivo, as revealed by GFP immunofluorescence and fluorescence 
microscopy analysis of muscle sections, (d-e) Lethally irradiated C57/BL6-CD45.1 
mice were transplanted with WBM cells isolated from C57/BL6-GFP-CD45.2 mice. 6 
weeks after BM transplantation, mononucleated cells prepared by non-injured (panel e) 
or injured (panel d) muscles were plated in methylcellulose M3434 (Kf/plate). The 
colonies were observed at day 8 by fluorescence microscopy.
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Figure 14. BM cells replenish the muscle-resident CD45+/Scal+ cells following BM  
transplantation.
C57/BL6-CD45.1 mice were lethally irradiated and transplanted with the whole bone 
marrow cells isolated from C57/BL6-GFP-CD45.2 mice. Mononucleated muscle cells 
were prepared from control irradiated (a) or transplanted mice (b) and analysed by flow 
cytometry for the expression of CD45.2, Seal and CD45.1, 4 and 21 days after 
irradiation, respectively.
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4.1.3 HSC-derived myogenic progenitors cannot extensively 
regenerate the muscle.
Our BM transplantation and co-culture experiments clearly demonstrated that 
particular BM-CD45+/Sca+ cells are able to migrate to and engraft in skeletal muscle 
and undergo myogenic specification and differentiation. However, in accordance with 
several previous reports, the frequency of this process was very low and more 
importantly these cells never gave rise to myogenic clones in culture. We decided to 
investigate whether the cause of this infrequency and deficiency, respectively, is the 
overwhelming myogenic activity of the endogenous muscle stem cells. It is possible 
that HSC-derived myogenic progenitors need a selective advantage in order to expand 
and fully exhibit their myogenic potential. To this end, we used Pax7'A mice as 
recipients in our BM transplantation experiments, since these mice are characterized by 
a progressive loss of satellite cells during lifetime and a strong impairement in muscle 
regeneration. BM cells derived from C57/BL6-GFP mice were intravenously injected in 
lethally irradiated PaxTA or Pax7+/~ mice, and six weeks after transplantation, ctx injury 
was used to induce muscle regeneration in the TA muscles. Three weeks later, the 
animals were sacrificed and GFP immunofluorescence was employed to identify GFP+ 
myofibers and to evaluate the contribution o f BM cells in muscle regeneration. 
Interestingly, the level of BM-derived myogenesis was similarly low in both recipients 
(Figure 15), revealing that BM cells cannot extensively regenerate the muscle, even in a 
model in which the muscle regeneration by the endogenous cells is highly impaired.
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Figure 15. BM cells cannot extensively regenerate the muscle.
Lethally irradiated Pax7+/' and P a xT ‘ mice were transplanted with the whole bone 
marrow cells isolated from C57BL/6-GFP mice. 6 weeks after BM transplantation, 
cardiotoxin was injected into the TAs and 3 weeks after the injury, immunofluorescence 
was performed on TA cryosections. (a) Fluorescence microscopy of GFP+ myofibers 
identified on muscle sections, (b) A bar graph reveals that the frequency of GFP+ 
myofibers is the same in PaxT ' and Pax7 ' recipient mice. Error bars represent the 
standard error of the means of six TA muscles of six different mice per group.
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4.1.4 Comparative gene expression profiling of BM- and muscle- 
derived CD45+/Scal+ cells reveals partial but extended 
reprogram ming.
To evaluate the extent o f myogenic specification of BM-CD45+/Scal+ cells in 
muscle at a global level, we performed gene expression profiling for a comparison of 
CD45+/Scal+ cells isolated from the bone marrow and the muscle. BM and muscle 
cells, but most probably of BM origin as suggested by our BM transplantation 
experiments (Figure 13a and Figure 14a and b), from C57BL/6 mice were sorted for the 
haematopoietic surface markers CD45 and Seal and their total RNA was extracted and 
used for microarray analysis. Focusing on the expression of myogenic transcription 
factors in both populations (Table 10), it appears that BM-CD45+/Scal+ cells do not 
express any of the transcription factors implicated in muscle regeneration. Ms- 
CD45+/Scal+ cells while showing the expression of Myf5, thus confirming our reporter 
assay, do not express other major myogenic transcription factors (e.g. Myod and PaxT). 
A wider inspection revealed that several secondary muscle-associated transcription 
factors (e.g. M sxl and TcflS) are expressed in the muscle-derived cell population. We 
also specifically checked the expression of 99 muscle-associated genes covering 
different biological categories (see Appendix). Transcription o f the muscle-associated 
genes by ms-CD45+/Scal+ cells is not limited to transcription factors but it is extended 
to the entire genome, and this expression pattern was restricted to ms-CD45+/Scal+ cells 
(Figure 16). A comparative gene expression analysis of BM- and ms-CD45+/Scal+ cells 
revealed that both cell populations express statistically significantly more 
haematopoietic genes than it would be expected by chance (right-tailed Fisher Exact
7 f\test: p=3.19x10' for BM and p=3.92xl0' for muscle), but the muscle-associated genes 
are over-represented only in the muscle-cell population (right-tailed Fisher Exact test:
p=0.00769, Figure 17a and enclosed electronic file). A functional analysis o f the genes 
expressed by the muscle-derived but not the BM-derived CD45+/Scal+ cells (see 
enclosed electronic file) clearly showed that the highest level of differential expression 
was detected for the over-representation o f genes involved in muscle biology (right­
tailed Fisher Exact test: p=4.31xlO'10, Figure 17b). More than 120 genes involved in 
several muscle processes, such as contraction and migration, were identified. These data 
suggest that at least a subset o f CD45+/Scal+ cells undergoes partial but extended 
reprogramming, once they are found in the muscle, and points out the importance of the 
microenvironment on the transcriptome of these cells.
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-----^ C !e ll  Population
Genes
BM-CD45+/Scal+ Muscle-CD45+/Scal+
Myf5 - +
Mrf4 - -
Myod - -
Myogenin - -
Pax3 - -
Pax7 - -
Mef2a + +
Mef2b - -
Mef2c + +
Mef2d - -
Meoxl - +
Meox2 - +
Msxl - +
Tcfl5 - +
Lbxlh - +
Table 10. Gene expression of myogenic transcription factors by CD45+/Scal+ cells.
CD45+/Scal+ cells were isolated either from the BM and the muscle o f 6 weeks-old 
C57/BL6 mice. Their total RNA was extracted and used for differential gene expression 
analysis (Affymetrix GeneChips). The gene expression o f several myogenic 
transcription factors is presented here (plus for expressed or minus for not-expressed).
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Figure 16. Ms-CD45+/Scal+ cells express numerous muscle-associated genes.
The expression of 99 muscle-associated genes in the BM- and the muscle-derived cells 
was checked (expressed and not-expressed are visualised as grey and black bars, 
respectively). These genes were categorized according to the muscle process in which 
the corresponding proteins are involved. A bar graph reveals that the expression of the 
muscle-associated genes by CD45+/Scal+ cells is extended in all the categories analysed 
and it is restricted to the muscle-derived population.
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Figure 17. Comparative gene expression analysis of BM- and ms-CD45+/S cal+ cells 
reveals differential expression of muscle-associated genes.
(a) The gene expression data of BM- (black bar) and ms- (grey bar) CD45+/S cal+ cells 
were compared using the Ingenuity Pathway analysis. A functional analysis specifically 
focused on haematopoiesis and muscle biology revealed that in both populations there is 
a statistically significant over-representation of the haematopoietic genes. On the 
contrary, the muscle genes were statistically significantly over-represented only in the 
muscle-derived population, (b) The functional analysis, o f the genes exclusively 
expressed by the muscle-derived population, identified the biological functions that 
were most significantly over-represented. The most statistically significant category was 
"skeletal and muscular system development and function". Here, only the five most 
statistically significant functions are shown. Bars represent the negative logarithms of 
the p values, which determine the probability that each assigned function is due to 
chance alone (right-tailed Fisher Exact test), and the horizontal lines define the 
statistical threshold (p=0.05).
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4.1.5 Pax7 and MyoD are not essential for the myogenic
differentiation and participation of HSC-derived myogenic
progenitors in muscle regeneration.
Surprisingly, the gene expression profile of CD45+/Scal+ cells indicated that 
MyoD and Pax7 are not transcribed. Due to their central role in muscle development 
and regeneration (see section 1.1.2.1), this prompted us to investigate their importance 
in the myogenic potential o f HSC-derived myogenic progenitors. In order to use PaxTA 
or MyoD'A mice as BM donors in BM transplantation experiments and to distinguish 
their cells from the recipient cells, it was essential to label their HSCs with high 
efficiency. Therefore, BM cells were infected overnight (MOI: 100) using a lentiviral
vector expressing eGFP under the human PGK promoter 14°. The transduction
efficiency was always higher than 90% for all samples as monitored by flow cytometry 
(Figure 18), and did not compromise the myogenic potential o f haematopoietic cells, 
since transduced cells efficiently fused to form myotubes in co-culture assay (Figure 
19a-d). In addition, to test their in-vivo incorporation into myofibers, the transduced 
BM cells from C57EL/6-CD45.2 mice were injected into lethally irradiated C57BL/6- 
CD45.1 mice. 6 weeks after BM transplantation, muscle regeneration was inducedin the 
TA muscles using cardiotoxin. We allowed complete muscle regeneration to take place 
(3-5 weeks) and finally sacrificed the mice and cryosectioned their TAs. Using GFP 
immunofluorescence, GFP+ muscle fibres were detected, demonstrating that the 
transduced haematopoietic cells retain their ability to participate in muscle regeneration 
(Figure 19e).
We repeated the experiment using MyoD'1' and PaxTA (CD45.2) mice as donors, 
and incorporation of the haematopoietic cells into myofibers was measured, counting 
the GFP+ muscle fibres. Surprisingly, BM cells lacking MyoD or Pax7 exhibited the
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same myogenic potential as cells derived from WT mice (Figure 20a). In order to study 
further if MyoD and Pax7 are important for the myogenic differentiation of HSC- 
derived myogenic progenitors, BM cells isolated from WT, PaxTA and MyoD'A mice 
were transduced with a virus encoding for eGFP under the control of a chimeric 
LTR/MCK promoter (Cesari et al, paper in preparation), with a consistent transduction 
efficacy greater than 90% for all strains, as measured by PCR detection of the provirus 
in CFUs (see sections 3.4.14 and 3.4.2). MCK  is expressed during the differentiation of 
myoblasts, both before and after the fusion, and this trait allowed us to study both 
myogenic specification and differentiation. The transduced cells were co-cultured with 
myoblasts, and several GFP+ single cells and myotubes were found (Figure 20b and c), 
indicating that HSC-derived myogenic progenitors can also express the early 
differentiation marker MCK. More importantly, this expression was not affected by the 
absence of Pax7 or MyoD (Figure 20d).
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Figure 18. Flow cytometry analysis of transduced BM cells.
BM cells were transduced (MOI 100, O/N) with a vector carrying eGFP under the 
hPGK promoter, (a) The transduction efficiency was evaluated 5 days after the infection 
by flow cytometry analysis. The filled and unfilled histograms represent non-transduced 
and transduced cells, respectively, (b) The transduced BM (CD45.2) cells were 
transplanted into lethally irradiated mice (CD45.1). 6 weeks after the BM 
transplantation, the blood of the recipient mice was analysed by flow cytometry for the 
expression of CD45.2 (donor cells) and eGFP.
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Figure 19. Lentiviral transduction does not impair the myogenic potential of 
hematopoietic cells.
BM cells were transduced with a vector coding for eGFP under the PGK promoter, (a -  
d) Transduced cells co-cultured with myoblasts contributed to myotubes formation as 
shown by GFP and MHCf immunofluorescence (a: MHCf, b: Hoechst, c: GFP and d: 
electronic merge), (e) Transduced haematopoietic cells were incorporated into TA 
muscle fibers, following BM transplantation and induction of muscle regeneration (GFP 
immunofluorescence).
WT Pax7 -/- MyoD-/-
c
250 pm
Figure 20. Pax7 and MyoD are not essential for the myogenic differentiation and 
the participation of HSC-derived myogenic progenitors in muscle regeneration.
(a) BM cells isolated from WT, MyoD'A or Pax7v' mice were transduced with a vector 
coding for eGFP under the PGK promoter and transplanted into lethally irradiated mice. 
6 weeks after the BM transplantation, cardiotoxin was injected into the TAs, and 5 
weeks after the injury, immunofluorescence was performed on the TA cryosections. 
Each dot represents one TA of one mouse and the horizontal bars represent the average 
number of GFP+ muscle fibres, (b-d) BM cells isolated from WT, MyoD 'A or Pax7'A 
mice were transduced with a vector coding for eGFP under the M CK/LTR  chimaeric 
promoter and co-cultured with myoblasts. Several GFP+ (MCW-expressing) cells were 
observed (b and c: GFP fluorescence and phase contrast microscopy of WT/BM co­
cultures, respectively), (d) A bar graph reveals that the BM cells lacking MyoD or Pax7 
express MCK  as frequently as WT cells. The error bars represent the standard errors of 
the means of six different experiments.
4.1.6 Myogenic specification and differentiation take place in the 
absence of Pax7.
Pax7-independence initially seemed in contrast with our hypothesis of a step­
wise myogenic differentiation of HSC-derived myogenic cells. In addition, in contrast 
to our findings, Seale and colleagues 45 have claimed that Pax7 is required for the 
myogenic commitment of the muscle-resident CD45+/Scal+ cells. Hence, PaxTA 
/Myf5nlacZ/+ and PaxTA/MLC3¥-nlacZ-E double transgenic mice were bred to ultimately 
confirm the Pax7-independence of the process. These mice express LacZ under the 
Myf5 or the MLC3F promoter, like Myf5nlacZ/+ and MLC3¥-nlacZ-E mice do, but also 
lack Pax7. Therefore, their utilisation allowed us to monitor the effect o f the Pax7 
absence on the expression of Myf5 and MLC, respectively. BM cells of these mice were 
used for myogenic co-cultures, and four days after proliferation (PaxTA/Myf5nlacZ/+ 
cells) or 2-3 days after differentiation (PaxTA/MLC3¥-nlacZ-E cells), several 6-gal+ 
cells were detected at frequencies (0.083 ± 0.027 and 0.09 ± 0.015, respectively) not 
significantly different from the ones observed for BM cells derived from Myf5nlacZ/+ 
(0.07 ± 0.025) and MLC3F-«/«cZ-E (0.096 ± 0.023) mice, which do not lack Pax7 
(Figure 21a).
Finally, we decided to investigate if  this Pax7-independence of myogenesis is 
restricted only to HSC-derived myogenic progenitors. Interestingly, the muscle 
preparations from Myf5nIacZ/+ and MLC3Y-nlacZ-E mice in the PaxTA or the WT 
background and culture o f their muscle cells in myoblast proliferation conditions 
resulted in cultures dominated by fibroblasts in the case of PaxTA mice instead o f the 
satellite-like clones observed in WT ones (Figure 21b). However, in the cultures of 
PoxTAIMyf5nlacZ/+ and PaxT^'/MLC3F-nlacZ-E mice, rare cells expressed Myf5 (at the 
end of the proliferation) and displayed MLC expression and myotubes formation (at the
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end of the differentiation), respectively, as revealed by X-gal staining (Figure 21b-f). 
Notably, most o f these cells did not give rise to myoblast clones (Wilcoxon test: 
p=0.0014 for MLC and p= 0.0312 for Myf5, Figure 21b and Table 11) and the few 
myoblast clones detected consisted of a remarkably decreased number of cells (unpaired 
t test: p<0.0001 for MLC and p<0.0001 for Myf5, Fig. 7c-f and Table 11). These data 
indicate that Pax7 is important for the formation and expansion of myoblast clones, and 
more importantly, demonstrate that myogenic specification (Myf5 expression) and 
differentiation (MLC expression) are Pax7-independent and this characteristic is shared 
both by the BM-derived and the muscle-resident myogenic progenitors.
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Figure 21. Pax7 absence impairs the formation and expansion of myoblast clones 
but not the myogenic specification and differentiation.
(a) Myogenic co-culture of the BM cells derived from Myf5n]acZJ" and MLC3E-nlacZ-E 
mice in a WT or a Pax7_/‘ background and subsequent X-gal staining. A bar graph 
reveals that the BM cells lacking Pax7 express Myf5 (grey bars) and MLC  (black bars) 
as frequently as the WT cells. The error bars represent the standard errors o f the means 
of six independent experiments, (b-f) X-gal staining of muscle preparations from the 
Myf5nlacZ/T (proliferation phase) and the MLC3E-nlacZ-E (differentiation phase) mice in 
a WT or a Pax7'/' background (b and c: P a x T ^ /M y fS ^ ^ , d: WT IMyf5nlacZ/+, e: P a x f '  
/MLC3¥-nlacZ-E and f: WT/MLC3F-i2/acZ-E).
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Mouse genotype Number of b- 
gal+ cells 
(xlO3)
Number of 
myoblast clones
Number of b-gal+ 
cells/myoblast clone
PaxT'-IMyf5"laca+ 0.5±0.1 6.8±1.2 56±9 (n=59)
V/VM)f5"'acZ,+ 61.2±10.8 124±21 472±31 (n=59)
PaxTA/MLCiV-nlacZ-E 0.2±0.04 2.5±0.4 42±4 (n=107)
WT/MLC3F-n/aeZ-E 28.5±10.4 82±31 358±17(n=117)
Table 11. Pax7 absence impairs the formation and expansion of myoblast clones.
The total number of b-gal+ cells, the number of myoblast clones and the number of b- 
gal+ cells per myoblast clone, as detected by X-gal staining of muscle preparations from 
the Myf5nIacZ/+ (proliferation phase) and the MLC3Y-nlacZ-E (differentiation phase) 
mice in a WT or a PaxT7' background. The numbers are mean values and standard errors 
of the means of six independent experiments, obtained by plating 105 total muscle cells.
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4.2 Pax7-overexpression activates the intrinsic myogenic 
potential of BM-CD45+/Scal+ cells.
The abovementioned data clearly demonstrate that certain BM-CD45+/Scal+ cells 
can undergo myogenic specification, differentiation and participation in muscle 
regeneration, but they never become identical to the satellite cells. Moreover, they 
confirm that Pax7 is associated with the myoblast-clone forming ability and the 
satellite-cell stem-cell characteristics, and show that it is not involved in BM-derived 
myogenesis. We considered the possibility that the inability of HSC-derived myogenic 
progenitors to behave as muscle stem cells is brought about by this Pax7 absence, and 
therefore we decided to investigate if the ectopic expression o f Pax7 in these cells 
would be sufficient for infusing them with the missing Pax7-associated and satellite-like 
properties and to render them muscle-stem cells or equivalent to satellite cells.
4.2.1 Pax7 up-regulation is sufficient to induce the myogenic 
specification and the clone-forming ability, but not the 
differentiation of BM-CD45+/Scal+ cells.
In order to ectopically express Pax7, efficiently and stably, in haematopoietic
stem/progenitor cells, we constructed a lentiviral vector, in which the Pax7 cDNA is
under the control the human P G K promoter (see section 3.4.1). Initially, 293T and HEL
cells were infected with the constructed vector, to test the transgene expression. The
Pax7 protein was successfully detected in HEL cells, using Western Blot (Figure 22a)
and flow cytometry (Figure 22b) and its correct nuclear sub-cellular localisation was
shown by immunofluorescence on 293T cells (Figure 22c-f).
BM cells derived from GFP/Myf5nlacZ/+ mice were isolated and transduced with
the lentiviral vector, encoding for Pax7 under the control of the PG K  promoter (MOI:
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100, overnight). The infected BM cells were either cultured alone in myoblasts 
conditions or co-cultured with unlabelled myoblasts and their transduction efficiency 
was typically 85%, as calculated by flow cytometry (Figure 23d). Importantly, certain 
GFP/Myf5nlacZ/+ BM cells over-expressing Pax7 formed myogenic clones containing 5— 
20 6-gal+ cells both in culture alone and in myogenic co-cultures (Figure 23a), while the 
non-transduced ones never did. However, the frequency of the A^/5-expressing cells in 
co-culture was comparable for both cell populations (Figure 23e), due to the rarity of 
these clones (5 ± 2.5 clones out of 4x105 cells plated, n=3). To ensure that the BM cells 
capable of this Pax7-activated intrinsic myogenic potential were the CD45+/Scal+ cells 
under study; we magnetically separated BM-Scal+ cells and therefore CD45+, since all 
the BM-derived Scal+ cells express CD45, from GFP/Myf5nlacZ/+ mice and we repeated 
the above co-culture experiment. The enrichment efficiency was higher than 85% 
(Figure 23b) and as it was expected, BM-CD45+/Scal+ cells generated myogenic clones 
with a higher frequency than WBM (Figure 23c).
Interestingly, the GFP/MLC3¥-nlacZ-E BM cells, transduced with Pax7, 
subsequently cultured alone and induced to differentiate, never expressed MLC, as 
revealed by the absence of any 6-gal+ cells after X-gal staining (n=6). We considered 
the possibility that Pctx7 over-expression inhibits the myogenic differentiation o f BM- 
CD45+/Scal+ cells, since it had been reported that Pax7 up-regulation inhibits the 
differentiation of satellite cells 60. To exclude this likelihood, we repeated the infection 
of the GFP/MLC3F-nlacZ-E BM cells with the Pax7 vector and we co-cultured them 
with myoblasts. Importantly, the Pax7 ectopic expression did not abolish the property of  
BM cells to express MLC in co-culture (Figure 23e). Overall, these data demonstrate 
that the ectopic expression of Pax7 in BM cells triggers the formation o f Myf5- 
expressing myoblast clones, independently from the interaction with myoblasts, but it is 
not sufficient to induce myogenic differentiation in vitro.
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Figure 22. Validation of a lentiviral vector encoding for Pax7.
(a-b) HEL cells were transduced with the Pax7 lentiviral vector and the Pax7 protein 
was detected both by Western Blot (a, MOI: 1) and flow cytometry (b, MOI: 5). The 
filled and unfilled histograms represent non-transduced and transduced cells, 
respectively, (c-f) 293T cells were infected with the Pax7 lentiviral vector (MOI: 10, 
overnight) and the expression of Pax7 was checked by immunofluorescence microscopy 
(c: phase contrast, d: Hoechst, e: Pax7 and f: electronic merge).
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Figure 23. Pax7 up-regulation is sufficient to induce myogenic specification and 
clones-forming ability, but not differentiation of BM-CD45+/Scal+ cells in vitro.
The BM cells isolated from GFP/Myf5n!acZ/^ or GFP/WiLC3¥-nlacZ-E mice were 
infected with a lentiviral vector carrying the Pax7 cDNA, (a-c) Culture and X-gal 
staining of the transduced WBM or BM -Scal+ GFP/Myf5nlacZ/~ cells, (a) A BM-derived 
A^/5-expressing myogenic clone, (b) BM cells magnetically enriched for Seal were 
checked for the expression of the marker by flow cytometry (the filled and unfilled 
histograms represent WBM and sorted cells, respectively), (c) A bar graph reveals that 
BM -Scal+ cells created more b-gal+ myoblast clones than WBM. (d-e) Co-culture with 
unlabelled myoblasts and X-gal staining of the transduced BM GFP/Myf5nlacZ/"or 
GFP/W[LC3¥-nlacZ-E cells (d): Flow cytometry analysis of Pax7- and GFT-expression 
(top panel: non-transduced BM cells and lower panel: transduced BM cells) shows high 
transduction efficiency, (e) A bar graph reveals that transduced BM cells, ectopically 
expressing Pax7, express Myf5 (black bars) and MLC  (grey bars) as frequently as non­
transduced ones.
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4.2.2 The P a x 7  ectopic expression has no detectable effect on the 
haematopoietic potential of BM cells.
In vitro, the activation of the intrinsic myogenic program of BM-CD45+/Scal+ 
cells, following Pax7 ectopic expression, encouraged us to investigate this phenomenon 
in vivo. Thus, we decided to use Pax:7-overexpressing BM cells as donors in BM 
transplantation experiments; but prior to this, we tested the feasibility of this approach 
by assessing whether the haematopoietic potential of BM-CD45+/Scal+ cells is affected 
by the ectopic expression of Pax7. BM cells were either transduced with the PGK.Pax7 
vector or mock-transduced and subsequently plated in methylcellulose media. The 
frequency o f haematopoietic clones was comparable for both populations (Pax7- 
transduced: 17.8 ± 1.6 CFUs and mock-transduced: 16.5 ± 1.1 out of 2x l04 cells plated, 
n=6), suggesting that the Pax 7-overexpression has no apparent effect on the 
haematopoietic colony-forming ability of BM cells.
We proceeded with the intravenous injection of Pax 7-overexpressing or mock- 
transduced C57BL/6/GFP/CD45.2 BM cells in lethally irradiated C57BL/6/CD45.1 
mice. The transduction of BM cells, able to repopulate the recipients, was verified by 
Southern blot and PCR analyses on their genomic DNA, specifically designed for the 
detection of the integrated provirus (Figure 24). Restriction digestion of the genomic 
DNA of BM cells isolated from the recipients (3.5 months following transplantation), 
with an enzyme specifically cutting twice the provirus, allowed us to appreciate the 
genomic stability of the integrated provirus, since one single band (expected digestion 
product size: 4500bp) was present in all BM-infected samples. Importantly, Pax7- 
transduced BM cells reconstituted the haematopoietic system of recipient mice similarly 
to mock-transduced cells and gave rise to all the haematopoietic lineages tested, as 
shown by the co-expression of the CD45.2 donor marker with B220, CD3 or C D llb  in
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peripheral blood (PB) cells analysed with flow cytometry (Figure 25a), three months 
after transplantation. The level of Pax7 expression was variable among the mice and the 
cell lineages and typically ranged between 30%-50%, as revealed by the intranuclear 
staining for Pax7 and flow cytometry (Figure 25b) .In addition, BM cells isolated from 
transplanted chimaeras, were used for a clonogenic assay and generated haematopoietic 
clones with similar efficiencies (Pax7-transduced: 17.5 ± 1 CFUs and mock-transduced: 
18.8 ± 0.7 out of 2x104 cells plated, n=6). All the above results, clearly demonstrate that 
Pax7 ectopic expression has no detectable effect on the haematopoietic potential of BM 
cells.
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Figure 24. Genomic stability of the integrated PGK.Pax7 provirus.
BM cells isolated from C57BL/6/GFP/CD45.2 mice were infected with the PGK.Pax7 
lentiviral vector mock-transduced and transplanted into lethally irradiated 
C57BL/6/CD45.1 recipients. After 3.5 months, BM cells from the transplanted mice 
were isolated for DNA extraction and Southern blot (upper panel) and genomic PCR 
(lower panel) analyses, to detect the integrated provirus and evaluate its genomic 
stability (mouse 1: mock-transduced and mice 2-6: transduced).
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Figure 25. Pax7-tranduced BM cells can reconstitute the haematopoietic system 
and give rise to all the haematopoietic lineages, in vivo.
BM cells isolated from C51BL/6/GFP/CD45.2 mice were infected with a lentiviral 
vector carrying the Pax7 cDNA or mock-transduced and transplanted in lethally 
irradiated C57BL/6/CD45.1 recipients, (a) Flow cytometry analysis of PB for CD45.2, 
B220 (left panels), CD3 (middle panels), and CD l ib  (right panels) expression, shows 
comparable reconstitution of all the three lineages by mock-transduced (top panels) and 
Pax7-trasduced (lower panels) BM cells, (b) Flow cytometry analysis of PB for Pax7, 
CD45 (left panels), B220 (middle panels), and C D llb  (right panels) expression, detects 
Pax7 in lymphoid and myeloid cell lineages.
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4.2.3 Pax7 over-expression increases BM-derived myogenesis in-vivo.
Chimeric mice transplanted with Pax7-transduced GFP/Myf5nlacZ/+ BM cells 
were used to assess in vivo the level of BM-derived myogenesis, following the Pax7- 
overexpression. Seven weeks after transplantation, the TA muscles o f transplanted mice 
were subjected to ctx injection, to induce muscle regeneration. Seven weeks following 
muscle injury, the mice were sacrificed and their TAs were cryosectioned and used for 
GFP immunofluorescence, to quantify the participation of BM cells to muscle 
regeneration. Notably, we observed a small but statistically significant increase (Mann 
Whitney test: p<0.05) of GFP+ muscle fibres in the TAs of mice transplanted with the 
BM cells transduced with Pax7, suggesting that Pax7 ectopic expression increases their 
in-vivo myogenic potential.
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Figure 26. Pax7  over-expression increases BM-derived myogenesis.
The BM cells isolated from C57BL/6/GFP/CD45.2 mice were either infected or non­
infected with the PGK.Pax7 lentiviral vector and transplanted into lethally iradiated 
C57BL/6/CD45.1 mice. Seven weeks later, cardiotoxin was injected into the TAs of the 
chimaeras, and 5 weeks after the injury, immunofluorescence was performed on TA 
cryosections. A bar graph shows that the BM cells transduced with Pax7 incorporate 
into muscle fibres more readilly than the non-transduced cells. The error bars represent 
the standard errors of the means of eight different experiments.
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5 Discussion
In 1998, our group had demonstrated that BM cells can participate in muscle 
regeneration 102. This observation has started an ongoing debate on the myogenic 
potential of the BM-derived cells, and more generally, on the plasticity of adult stem 
cells 143. The terms adult stem cell plasticity and transdifferentiation have acquired 
controversial and provocative meanings, and in this debate the myogenic potential o f  
BM cells has become a frontline issue, since most studies investigated this 
phenomenon. Unfortunately, this extensive study has produced controversial data, 
mainly due to the infrequency of the event 105>106>108>114>127 j h e ability of BM cells to 
activate a myogenic program and to be entirely reprogrammed, and their lineage 
relationship with the satellite muscle-stem cells remain still uncertain. This research 
investigated these issues and the data obtained are interpreted in this section.
5.1 Molecular mechanism regulating the BM-derived 
myogenesis.
The existence of a myogenic program able to regulate the transition of BM cells 
to muscle cells is surely the most debated aspect of BM-derived myogenesis. It has been 
reported that BM cells are able to express muscle-specific and satellite-marker genes, 
like Myf5, c-met, CD34, M-cadherin and Pax7, prior to their fusion to the muscle fibre 
both in vitro and in vivo 105’108,126,127. However, the reproduction o f these results was 
partial 127 or impossible 114, casting doubts over the integrity of these studies and 
proposing the idea of direct and accidental fusion of BM cells to the myofiber.
98
5.1.1 BM-CD45+/Scal+ cells undergo myogenic specification and 
differentiation and incorporation into myofibers.
In our experiments, the utilisation of reporter genes under the control o f muscle- 
specific promoters and knock-out mice, and the gene expression profiling of 
CD45+/Scal+ cells have enabled a more detailed and comprehensive investigation of the 
phenomenon. Specifically, co-culture of the Myf5nIacZ/+ BM-derived cells, enriched for 
CD45, Seal, and c-kit, with myoblasts revealed that certain BM-CD45+/Scal+ cells can 
express (although infrequently) the satellite marker Myf5, before fusion. Furthermore, 
the utilisation o f MLC3F-nlacZ-E mice in the co-culture assay has allowed us to detect 
single cells that express MLC and myotubes containing BM-derived nuclei. Similar 
results were obtained when BM cells, previously transduced with a lentiviral vector 
encoding for eGFP under the control of a chimeric LTR/MCK promoter, were used for 
the co-culture experiments. Interestingly, our BM transplantation experiments revealed 
that mononuclear BM-CD45+/Scal+ cells isolated from regenerating muscle also 
express Myf5 after co-culture with myoblasts. These results demonstrate that BM- 
derived haematopoietic stem/progenitor cells can (approximate frequency 0.1%) 
undergo myogenic specification and differentiation. Notably, our results do not exclude 
that other BM sub-populations could contribute to the muscle-fibre formation without 
any previous myogenic pre-specification, as it had been reported previously 106,114,127.
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5.1.2 BM-derived myogenesis is MyoD and Pax7 independent.
The gene expression profiling of the CD45+/Scal+ cells isolated from the muscle 
ultimately confirmed the expression of Myf5, MLC and MCK. Nevertheless, MyoD and 
Pax7 were not expressed, indicating that these two important myogenic transcription 
factors are not involved in the participation of BM-CD45+/Scal+ cells in muscle 
regeneration. Importantly, the experiments of co-culture and BM transplantation, with 
BM cells from JWT, PaxTA or MyoD'A mice transduced with the MCK.eGFP or the 
PGK.eGFP vector, demonstrated that Pax7 and MyoD are not essential for M CK  
expression and contribution of BM-derived haematopoietic cells in muscle regeneration. 
The MyoD-independence of this process can be explained by its well-established 
genetic redundancy with Myf5 144. Interestingly, developmental studies reported that 
MyoD and Myf5 are activated in distinct muscle-cell lineages, suggesting that do not 
compensate for the absence of each other within the same cell but they operate and 
determine separate muscle-cell lineages 145. Although, this complementation at cellular 
level does not seem to be the case for the adult muscle stem cells, since satellite cells 
express both genes (see section 1.1.2.1), this could explain the solitary Myf5 expression 
in HSC-derived myogenic progenitors.
Notably, Pax7 has distinct but also partially overlapping functions with Pax3 
both during muscle development146 and regeneration 44,47, and therefore we considered 
the possibility that the Pax7-independence observed is conferred by Pax3-activity. 
However, we excluded this likelihood, since ms-CD45+/Scal+ cells did not express 
Pax3, as revealed by the DNA microarray data. The Pax7-independence initially 
appears to contradict our hypothesis of a step-wise myogenic differentiation o f  
haematopoietic cells, owing to the central role that Pax7 has in myoblast proliferation 
and self-renewal 44‘47. Furthermore, it is opposing with the Pax7-dependent myogenic
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specification suggested by Seale and colleagues 78. On the other hand, Asakura and 
colleagues 71 have described the Pax7-independence of the myogenic differentiation of 
ms-SP cells, which also exhibit both haematopoietic and myogenic potential. To 
undoubtedly clarify the role o f Pax7, we performed BM-myoblast co-cultures, utilizing 
Pax TAI Myf5nIac7/+ and PaxTA/MLC3V-nlacZ-E mice, and we detected PaxTA BM- 
derived haematopoietic cells able to express Myf5 and MLC. In addition, muscle cells 
derived from these mice also expressed Myf5 and MLC. These findings not only 
confirm that HSC-derived myogenic progenitors incorporate into the myofibers in a 
Pax7-independent manner but they also demonstrate that Pax7 is not necessary for 
myogenic specification and differentiation of both the haematopoietic and the muscle 
cells.
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5.1.3 Indications for alternative myogenic programs.
The acknowledgment o f Pax7- and MyoD- independence together with the 
absence of other important myogenic transcription factors, such as Mrf4, myogenin and 
Pax3, challenges the step-wise myogenic specification and differentiation observed in 
our in-vitro and ex-vivo gene reporter assays. It has been reported that Myf5 fails to 
support myogenic differentiation in myogenin'^IMyoD'^IMrf^' triple mutant embryos 
(although it was sufficient to initiate myogenic specification) 147, and therefore it 
appears difficult to envisage a myogenic program that excludes all the major myogenic 
transcription factors except for Myf5. However, a more detailed inspection o f the DNA  
microarray data allowed the detection of several secondary muscle-associated genes, 
like Msxl 148 and Mnf 149, and transcription factors important for the muscle 
development and the migration and myogenic specification o f the muscle precursor 
cells (e.g. Meoxl 15°, Meox2 I50, Tcfl5 151 and Lbxhl 152). It is tempting to speculate 
that the cooperative expression o f these muscle-assosiated genes is sufficient to drive 
myogenic specification, differentiation and contribution to muscle fibre formation.
It is also probable that the Pax7-lacking cells follow an alternative or partial 
myogenic program. Recently, it was reported that the ectopic expression o f a Pax7 
dominant negative mutant affects the expression of MyoD but not Myf5. The same 
ectopic expression in the Myf5+/' satellite cells has no effect on their differentiation, 
while the transduced Myf5'A satellite cells do not differentiate. These results suggested 
that either Pax7, acting via MyoD, or Myf5 are required for the myogenic 
differentiation of satellite cells 44. The existence o f these two parallel genetic pathways 
explains the Pax7-independence displayed by HSC-derived myogenic progenitors, and 
taken together with our array data, showing the absence of Pax7 and PaxS expression, 
suggests that the Pax7 pathway is inactive and only the Myf5 pathway is active in these
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cells. It would be interesting to investigate whether the myogenic specification, 
differentiation and contribution to muscle regeneration of BM-CD45+/Scal+ cells is 
dependent on Myf5, and therefore whether Myf5 drives BM-derived myogenesis or it is 
simply one of the genes activated by the muscle microenviroment.
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5.2 Nuclear reprogramming of BM-CD45+/Scal+ cells and 
muscle microenviroment.
Our reporter gene assays did not reveal the degree o f commitment and nuclear re­
programming that HSC-derived myogenic cells reach. Fortunately, the DNA microarray 
analysis permitted us to assess the extent of myogenic reprogramming undertaken by 
these cells. The analysis of the gene expression profiling of the BM-derived and the 
muscle-resident CD45+/Scal+ cells revealed that only the latter cell population 
expresses statistically significantly more muscle-associated genes than it would be 
expected by chance. This was verified both by the comparative gene expression analysis 
between the cell populations and the functional analysis performed on genes exclusively 
expressed by the ms-CD45+/Scal+ cells. Considering that the muscle-derived 
CD45+/Scal+ cells most probably have a BM origin, as it is strongly suggested by our
  1 OQ 1 o o
BM transplantation experiments and previous studies ’ , the aforementioned
differences between the cells isolated from BM and muscle reveal the importance of the 
microenvironment on the transcriptome and the potential of these cells. This is further 
supported by the necessity that these cells show for co-culture with myoblasts, in order 
to differentiate in vitro.
In agreement with previous reports (see section 1.2.2), BM-derived CD45+/Scal+
cells isolated from the muscle retained their haematopoietic potential, as shown both by
the statistically significant over-representation of haematopoietic genes (DNA
microarray data) and their ability to generate haematopoietic clones. The muscle
regeneration, induced by ctx injection, abolished this latter ability o f BM-derived
CD45+/Scal+ cells, suggesting a change in their fate. However, it is not possible to
associate this change with the acquirement of the myogenic potential, since BM-
CD45+/Scal+ cells exist as a heterogenous population and our experiments cannot
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demonstrate that the cells losing their haematopoietic potential obtain myogenic 
potential and finally participate in muscle regeneration.
Lastly, although our results strongly suggest an extended activation of muscle 
genes, it is unclear if  these cells complete the BM to muscle transition and express the 
whole repertoire o f the muscle genes after their fusion to muscle fibre. Indeed, several 
studies had reported that the BM cells incorporated into the muscle fibres fail to 
produce the late muscle-differentiation markers, such as dystrophin 114 or 6-sarcoglycan 
109, and proposed models, predicting that different degrees of reprogramming can exist 
153 and that a threshold must be reached to achieve the transcription of all the muscle 
genes 154.
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5.5 Relationship between HSC-derived myogenic progenitors 
and satellite-stem cells.
Previous studies had claimed that BM cells are capable of occupying the 
sublaminar space, undergoing myogenic specification and giving myoblast-like clones 
once isolated from the muscle, suggesting that these cells can actually become satellite 
cells 105’108. However, this idea has been questioned by numerous reports, addressing 
their ability to express muscle-specific genes prior to fusion 106’114>127.
In our experiments, CD45+/Scal+ cells, isolated directly from the BM or the 
muscle tissue, did not exhibit the satellite-cell-associated ability to form myoblast 
clones, demonstrating that they are not identical to satellite cells. The BM 
transplantations in PaxTA recipient mice, clearly showed the inability o f these cells to 
extensively regenerate the muscle even in mutant mice in which the satellite-cell 
population is greatly diminished, and therefore ensure that the always-reported scarce 
participation of BM cells in muscle regeneration is not due to competition with the 
endogenous satellite cells. Finally, the comparison of our genomics data on 
CD45+/Scal+ cells with the known properties of satellite-cell-derived myoblasts reveals 
the partial reprogramming of the former and demonstrates their distinction from the 
latter. Concerning, the previously claimed localisation of BM cells in the satellite-cell 
niche 105’108’155, our experiments did not address this feature and consequently we cannot 
exclude it. However, this characteristic alone is not sufficient to elevate these BM cells 
to muscle stem cells, since the satellite-cell population is heterogenous and thus not all 
the cells located in this space are true muscle stem cells. Overall, this study 
unequivocally establishes that BM-CD45+/Scal+ cells cannot be considered muscle 
stem cells.
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5.4 The Pax7 importance on the muscle-stem-cell 
characteristics.
We previously discussed the Pax7-independence of myogenic specification and 
differentiation of both muscle cells and BM-derived haematopoietic stem/progenitor 
cells. However, we ought to underline that the myogenic progenitors derived from the 
PaxTA muscles gave rise to very few myogenic clones, containing a decreased number 
of cells and hence not exhibiting this characteristic Pax7-associated propagation 
property of satellite cells. Another study in Pax7LacZ/LacZ mice revealed that there is an 
interstitial Pax7-independent myogenic population distinct from the satellite cell 
compartment 47. Whether the myogenic progenitors isolated from the muscle o f PaxTA 
mice is a distinct population from satellite cells or they are satellite cells deprived from 
their self-maintaining and proliferation ability is not addressed by the current 
experiments, but it can be studied using the PaxTAIMyf5nlacZ/+ and the Pax7"/'/MLC3F- 
nlacZ- E mice.
Notably, the HSC-derived myogenic progenitors, described in our study, never 
gave rise to myogenic clones nor behaved as muscle-stem cells. Remarkably, activation 
of the Pax7 pathway in these cells, using the overexpression o f Pax7, infused to them 
the ability to generate myoblast clones and increased their in-vivo myogenic potential. 
All the above observations not only confirm that Pax7 is closely linked with the 
propagation and the self-renewal of satellite cells, but more importantly establish it as 
the key factor for muscle-stem-cell competence.
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6 Conclusive remarks and future perspectives.
To sum up, we propose that BM-derived haematopoietic stem/progenitor cells can 
undergo myogenic specification, differentiation and participation in muscle 
regeneration; but they never become identical to the satellite cells, as previously 
reported. Moreover, this process is MyoD- and Pax7-independent and is also shared by 
certain muscle-resident myogenic progenitors. Our findings do not provide evidence of 
adult stem cell plasticity or transdifferentiation of the cells under study as these are very 
strictly defined 143, since most o f the criteria (i.e. total nuclear reprogramming, cell 
commitment) are not fulfilled. However, we show the myogenic reprogramming of 
CD45+/Scal+ cells by expression profiling and their step-wise myogenic specification, 
leading to contribution to the myofiber formation. Our study demonstrates that these 
cells can change fate and show a degree of plasticity, in the broader sense o f the term.
The first reports of BM-derived myogenesis created hope for the treatment of 
muscle diseases, since BM cells are readily accessed, compared to the muscle-resident 
stem cells, and they are already used in medicine for the treatment of blood disorders. 
Unfortunately, these expectations were not encountered and the initial enthusiasm was 
followed by a general depreciation. Nevertheless, even though it is crystal clear that 
there will be no current or near-future clinical application of these cells, we believe that 
studying and deeply understanding the basic biology of BM-derived myogenesis is still 
relevant to the forthcoming cell therapy. Additionally, the investigation of the 
reprogramming of these BM cells could give useful insights in stem-cell biology and 
cell-fate determination, and thus we support the continuance of this research.
Specifically, it would be interesting to further examine the role o f Myf5 in the
myogenic reprogramming of BM-derived haematopoietic stem/progenitor cells and to
this end we are currently performing BM transplantation experiments, using Myf5
108
mutant mice as donors. Impairment in the participation of the Myf5‘/_ BM cells in the 
muscle regeneration would unequivocally confirm that an alternative myogenic program 
regulates BM-derived myogenesis. The effect of Pax 7-overexpression on the muscle- 
stem-cell characteristics of HSC-derived myogenic progenitors is also of particular 
interest. Whether the BM cells ectopically expressing Pax7 only partially gain satellite­
cell properties or they become identical to them is not elucidated by our experiments. 
The gene expression profiling of these cells would facilitate us to definitely appreciate 
the true outcome o f Pax7-transduction and more generally evaluate the result o f such 
program manipulations in the stem-cell fate.
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TNF6: Tumor Necrosis Factor 5
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WBM: whole bone marrow
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Genesymbol Biological Category
Actal Structural proteins
Act c l Structural proteins
Actn2 Structural proteins
Actn3 Structural proteins
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Arx Transcription factors/Signalling
Atp2al excitability
Atp2a2 excitability
Bgn adhesion/Extracellular Matrix Proteins
Casql excitability
Casq2 excitability
Cd34 adhesion/Extracellular Matrix Proteins
C dhll adhesion/Extracellular Matrix Proteins
Cdhl5 adhesion/Extracellular Matrix Proteins
Cdh2 adhesion/Extracellular Matrix Proteins
Ccknlc Transcription factors/Signalling
Chrnal excitability
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Cryab Transcription factors/Signalling
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Des Structural proteins
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Myhl Structural proteins
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M yll Structural proteins
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Nfatc2 Transcription factors/Signalling
Nfatc4 Transcription factors/Signalling
Nfic Transcription factors/Signalling
Nfix Transcription factors/Signalling
Nog Transcription factors/Signalling
Pax3 Transcription factors/Signalling
Pax7 Transcription factors/Signalling
Peg3 Transcription factors/Signalling
Pfkm Metabolism
Pkm2 Metabolism
Pin excitability
Prkcq Transcription factors/Signalling
Pva excitability
Sgca adhesion/Extracellular Matrix Proteins
Sixl Transcription factors/Signalling
Six4 Transcription factors/Signalling
Tcap Structural proteins
Tcfl5 Transcription factors/Signalling
Tncc Structural proteins
Tnnc2 Structural proteins
Tnnil Structural proteins
Tnni2 Structural proteins
Tnni3 Structural proteins
Tnntl Structural proteins
Tnnt2 Structural proteins
Tnnt3 Structural proteins
Tpml Structural proteins
Tpm2 Structural proteins
Tpm3 Structural proteins
Ttn Structural proteins
Twistl Transcription factors/Signalling
Uncx4.1 Transcription factors/Signalling
Vcaml adhesion/Extracellular Matrix Proteins
Zfpl48 Transcription factors/Signalling
